Selective Affinity-Based Probe for Oncogenic Kinases Suitable for Live cell Imaging

Claudio Zambaldo,^{*a*} Kalyan K. Sadhu,^{*a*} Ganesan Karthikeyan,^{*a*} Sofia Barluenga,^{*a*} Jean-Pierre Daguer, ^{*a*} Nicolas Winssinger,^{**ab*}

Supplemental infomation

1. General techniques	р 1
2. General procedure for the synthesis of RA	p 2
3. Strucure and charachetrization of RA1-74, compound 8 and 9	p 3
4. Enzymatic inhibition of EGFR	p 33
5. Cellular inhibitions of EGFR auto phosphorylation	p 33
6. Covalent labeling with Cy3-RA1	p 34
7. Imaging studies with Cy3-RA1	p34
8. List of kinase with less than 50% residual binding	p35
9. Affinity based capture from crude cell extract	p36
Figure S1	p37

General Techniques. Chemicals were purchased and used as received. Reactions were carried out under ambient conditions unless stated otherwise. Anhydrous solvents were obtained by passing them through commercially available alumina columns (Innovative Technology Inc. RVA). Standard syringe techniques were applied for the transfer of dry solvents and air- or moisture-sensitive reagents. Reactions were followed using TLC on silica gel-coated alumina plates (Merck 60 F₂₅₄) with the indicated solvent mixture. Detection was performed with UV-light (254 nm), and/or by heating after dipping into a solution of either KMnO₄ (10 g/L), K₂CO₃ (67 g/L) and NaOH (0.83 g/L) in H₂O or ninhydrin (33 g/L) in ethanol. ¹H/¹³C NMR spectra were recorded at ambient temperature on a Bruker DMX 400 machine in the specified deuterated solvents. Chemical shifts are given in ppm with respect to the residual undeuterated solvent signal as internal standard. Coupling constants are reported as Jvalues in Hz. The following abbreviations were used to explain the multiplicities: s = singlet, d =doublet, t = triplet, q = quartet, quin = quintet, dd = doublet of doublet, m = multiplet, br = broad. Column or flash chromatography was carried out using Merck silica gel (particle size 40-63 µm). LC-MS were recorded using an HP1100 series or Thermo Electron Corporation HPLC with a Thermo Finnezau Surveyor MSQ mass spectrometer system; a Thermo Scientific column (50 x 2.1 mm) was used. Fluorescence microscopic images were recorded using a Nikon Eclipse Ti inverted fluorescence microscope and a Photometrices Cool Snap HQ² CCD camera (Nikon). The filter sets used were Semrock Bright Line Exciter 325-375, Dichroic 405, and Emitter 435-485 for DAPI; Exciter 460-495,

Dichroic 505, and Emitter 510-560 for **FA**; Exciter 520-555, Dichroic 558, and Emitter 560-590 for **Cy3-RA1 (8).** Nikon NIS-Elements AR 3.10 imaging software was used for imaging.

Abreviations. DIPEA = N,N-Diisopropylethylamine; EOMCl = (chloromethoxy)ethane; PE = petroleum ether; DMF = N,N-Dimethylformamide.

Procedure A: General procedure for the esterification with DIC activation: To a stirred solution of the corresponding acid (1.0 equiv) in DMF, was added DIC (1.0 equiv) and the resulting solution was stirred at 23 °C for 10 min. Then the corresponding alcohol (1.0 equiv) and Et_3N (1.2 equiv) were added and the mixture was stirred overnight. Evaporation of the solvents followed by column chromatography (PE/ EtOAc) gave the desired ester.

Procedure B: General procedure for the Mitsunobu esterificaton: To a stirred solution of the acid (1.0 equiv), alcohol (1.0 equiv) and triphenylphosphine (1.0 equiv) in THF, was added dropwise DIAD (1.0 equiv), the resulting solution was stirred at 23°C for 14 hours. The reaction mixture was evaporated in vacuo and purified by column chromatography (PE/EtOAc) to give the corresponding ester.

Procedure C: General procedure for the esterification with NHS: To a stirred solution of acid (1.0 equiv) in THF, NHS (1.0 equiv) and DCC (1.0 equiv) were added and the resulting mixture was stirred at 23 °C for 4 hours. Evaporation of solvents gave the crude NHS intermediate. The crude NHS intermediate was reacted with the corresponding alcohol which was pre-treated with NaH (1.0 equiv) in THF at 23 °C. The reaction mixture was quenched with water and extracted with ethyl acetate, dried over Na_2SO_4 evaporated and purified by column chromatography to give the corresponding ester.

Procedure D: General procedure for the amidation with DIC or EDC activation: 2-hydroxy-5nitro benzoic acid (1a) (1.0 equiv) and DIC or EDC.HCl (1.0 equiv) in DMF (0.2 M) were stirred at 23°C for 15 min, then the corresponding amine (1.0 equiv) was added and stirring was continued for 18 hours. Evaporation of the solvents followed by column chromatography (PE/EtOAc 10:1) gave the desired amide.

Procedure E: General procedure amidation with oxalyl chloride activation. To a stirred solution of the corresponding acid (1.0 equiv) in dry CH_2Cl_2 (0.2 M) under N_2 were added (COCl)₂ (1.3 equiv) and dropwise DMF (cat.) and stirred until the gas evolution had ceased (5 min). This solution was added directly to the appropriate amine (1.1 equiv) and NEt₃ (1.5 equiv) in dry CH_2Cl_2 (0.3 M) under N_2 at 0 °C and then stirred for 10 min at 23 °C. After quenching with sat. NaHCO₃ (aq) the mixture was extracted with EtOAc twice and the combined organic layers were dried over Na₂SO₄. Evaporation of the solvents followed by column chromatography (PE/EtOAc 10:1) gave the desired amide.

Procedure F: General procedure for the reduction with zinc.¹ Following a literature procedure, to a solution of the appropriate nitro compound (1.0 equiv) in dry CH_2Cl_2 (0.036 M) were added at 0 °C zinc dust (14.0 equiv) and acetic acid (150 equiv). After stirring 10 min at room temperature, the mixture was filtered over Celite[©], quenched with sat. NaHCO₃ (aq.) and extracted with EtOAc (3x). The organic layers were dried over Na₂SO₄ and concentrated to give the crude amine, which was used in the subsequent reaction without further purification.

Procedure G: General procedure for the addition of the Michael acceptor: To a stirred solution of the corresponding crude amine (1.0 equiv) in dry CH_2Cl_2 (0.2 M) was added at -40 °C (or at 0 °C when protected substrates were used) DIPEA (1.2 equiv) and dropwise acryloyl chloride (0.9 equiv) and stirring was continued for 15 min. After quenching with sat. NaHCO₃ (aq), the mixture was extracted with CH_2Cl_2 (3x) dried over Na₂SO₄ and the solvent was evaporated. Column chromatography (PE/EtOAc) gave the desired acrylate. In the case of propiolic acid the following procedure GI was used. GI: To a solution of propiolic acid (2.0 equiv) in DCM was added DCC (2.0 equiv) and stirred at 23 °C for 10 min and the amine (1.0 equiv) and DMAP (20 mol%) were added and further stirred for 15 min. The reaction mixture was treated with aq NaHCO₃ and extracted with ethyl acetate. The crude material was purified by flash chromatography to give the corresponding amide.


Procedure H: General procedure for the EOM-protection To a stirred solution of the alcohol (1.0 equiv) in DMF (0.16 M) was added at 0 °C DIPEA (1.5 equiv) and dropwise EOMCl (1.5 equiv) after which stirring was continued for 24 hours. NaHCO₃ (sat. aq) was added to the reaction mixture after which an extraction with Et_2O (3x) was carried out. The combined organic layers were dried over Na₂SO₄, after which the solvent was evaporated and column chromatography (PE/EtOAc 3:1) was performed to give the protected derivative.

Procedure I: General procedure for the EOM deprotection. To a stirred solution of the corresponding EOM-ether protected compound (1.0 equiv) in MeOH (0.05 M) was added sulfonic acid resin (10.0 equiv, 3.0 mmol/g) at 23°C. After 6 hours the mixture was filtered and the solvent was evaporated. The crude product was purified by column chromatography (PE/EtOAc 3:1) to afford the desired alcohol.


Procedure J: General procedure for reduction with Pd/C: To a solution of the corresponding nitro compound (1.0 equiv.) in MeOH (3 mL) was added 5% Pd/C (40 mol%). The mixture was stirred overnight at 23°C under a H_2 atmosphere (balloon). Then, the catalyst was removed upon filtration through a short pad of celite eluting with MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography to afford the corresponding amine .

Procedure K: General procedure for deprotection of Trimethyl silyl ethyl group: To a solution of the corresponding TMSE ester in THF was added TBAF (4 equiv) and stirred at 23°C for 6 hours. The reaction mixture was quenched with aq. NH₄Cl and extracted with ethylacetae. The organic layer was extracted with sat. NH₄Cl_(aq) (X 2). The crude acid was used as such in next step.

¹ Belén Cid, M.; Duce, S.; Morales, S.; Rodrigo, E.; Luis García Ruano J. Nitrophenylacetonitriles as Versatile Nucleophiles in Enantioselective Organocatalytic Conjugate Additions. *Org. Lett.* **2010**, *12*, 3586-3589.




1-(pyridin-2-yl) ethyl 2-hydroxy-5-propiolamidobenzoate (RA1): Starting from compound **1a** and using procedure B followed by F and finally GI yielded **RA1** in a 43% over all yield. $R_f = 0.37$ (PE/EtOAc: 1/1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.06 (d, J = 2.8 Hz, 1H), 7.66 (dd, J = 8.8, 2.8 Hz, 1H), 7.47-7.35 (m, 5H), 6.98 (d, J = 8.8, Hz, 1H), 6.16 (q, J = 6.8 Hz, 1H), 2.95 (s, 1H), 1.72 (d, J = 6.8 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₇H₁₅N₂O⁺: 311.10; found: 311.24.




RA2

3-bromophenyl 5-acrylamido-2-hydroxybenzoate (RA2): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA2** in a 15% over all yield. $R_f = 0.43$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.2$ (s, 1H), 8.38 (d, J = 2.0 Hz, 1H), 7.68 (dd, J = 8.8, 2.0 Hz, 1H), 7.49-7.37 (m, 4H), 6.48 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.0 Hz, 1H), 5.81 (dd, J = 10.4, 0.8 Hz, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₆H₁₃BrNO₄⁺: 360.90; found: 362.09.




RA3

2-Hydroxy-5-propiolamido-*N*-(thiophen-2-ylmethyl)benzamide (RA3) Starting from compound 1a and using procedure D followed by F and finally E yielded RA3 in a 20% over all yield. $R_f = 0.35$ (PE/EtOAc 1:1); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.25 (s, 1H), 8.02 (d, J = 2.4 Hz, 1H), 7.77 (br s, 1H), 7.24 (dd, J = 5.2, 0.8 Hz, 1H), 7.19 (dd, J = 8.4, 2.4 Hz, 1H), 7.04 (d, J = 3.2 Hz, 1H), 6.97-6.93 (m, 3H), 4.78 (d, J = 5.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₅H₁₃N₂O₃S⁺: 301.07; found: 301.17.




5-acrylamido-2-hydroxy-N-(2-(thiophen-2-yl)ethyl)benzamide(RA4) Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA4** in a 20% over all yield. $R_f = 0.35$ (PE/EtOAc 1:1);¹H (MeOD, 400 MHz, 25 °C) $\delta = 8.02$ (d, J = 2.4 Hz, 1H), 7.58 (dd, J = 8.8, 2.4 Hz, 1H), 7.24 (dd, J = 4.0, 0.8 Hz, 1H), 6.97-6.89 (m, 3H), 6.39 (t, J = 2.8 Hz, 2H), 5.78 (dd, J = 9.2, 2.4 Hz, 1H), 3.67 (d, J = 7.2 Hz, 2H), 3.17 (t, J = 7.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₆H₁₇N₂O₃S⁺: 316.08; found: 317.22.



RA5

3-chloro-4-fluorophenyl 5-acrylamido-2-hydroxybenzoate(RA5) Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA5** in a 15% over all yield. $R_f = 0.28$ (PE/EtOAc 6:4);¹H (MeOD, 400 MHz, 25 °C) $\delta = 10.2$ (s, 1H), 8.38 (s, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.31 (d, J = 6.0 Hz, 1H), 7.19-7.09 (m, 2H), 7.04 (d, J = 8.8 Hz, 1H), 6.46 (d, J = 16.8 Hz, 1H), 6.24 (dd, J = 16.8, 10.4 Hz, 1H), 5.81 (d, J = 10.0 Hz, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For $C_{16}H_{12}CIFNO_4^+$: 335.03; found: 336.18.




RA6

5-Acrylamido-2-hydroxy-*N***-(4-phenylbutan-2-yl)benzamide (RA6)** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA6** in a 44% over all yield. $R_f = 0.45$ (PE/EtOAc 1:1); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.47 (br s, 1H), 8.03 (s, 1H), 7.39 (s, 1H), 7.28-7.14 (m, 6H), 6.93 (d, J = 8.8 Hz, 1H), 6.45-6.37 (m, 2H), 6.28 (dd, J = 17.2, 10.4 Hz, 1H), 5.80 (d, J = 10.4 Hz, 1H), 4.24 (quin, J = 7.6 Hz, 1H), 2.69 (t, J = 8.0 Hz, 2H), 1.96-1.83 (m, 2 H), 1.28 (d, J = 5.2 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For C₂₀H₂₃N₂O₃⁺: 339.17; found: 339.28.




5-acrylamido-*N*-(**2-bromophenethyl**)-**2-hydroxybenzamide (RA7):** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA7** in a 35% over all yield. $R_f = 0.37$ (PE/EtOAc 2:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 12.3$ (s, 1H), 8.19 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.43(s, 1H), 7.28 (s, 2H), 7.18-7.10 (m, 2H), 6.95 (d, J = 8.4 Hz, 1H), 6.80 (s, 1H), 6.44 (d, J = 16.4 Hz, 1H), 6.25 (dd, J = 16.8, 10.0 Hz, 1H), 5.80 (d, J = 10.4 Hz, 1H), 3.71 (t, J = 7.2 Hz, 2H), 3.10 (t, J = 7.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₈H₁₈BrN₂O₃⁺:390.04; found: 390.16.




RA8


1-phenylethyl 3-acrylamido-4,6-dihydroxy-2-methylbenzoate (RA8): Starting from compound $1b^2$ and using procedure J followed by G, K and finally E yielded **RA8** in a 32% over all yield. $R_f = 0.3$ (PE/EtOAc 2:3); ¹H (MeOD, 400 MHz, 25 °C) $\delta = 7.46$ (d, J = 7.6 Hz, 2H), 7.39 (t, J = 8.4 Hz, 2H), 7.32 (d, J = 7.2 Hz, 1H), 6.51 (dd, J = 17.2, 10.4 Hz, 1H), 6.37-6.32 (m, 2H), 6.16 (q, J = 6.4 Hz, 1H), 5.79 (dd, J = 10.0, 1.6 Hz, 1H), 1.69 (d, J = 6.8 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For $C_{19}H_{20}NO_5^+$: 342.13; found: 342.14.



5-Acrylamido-*N***-benzyl-2-hydroxybenzamide (RA9)** Starting from compound **1a** and using procedure D followed by F and finally G yielded RA9 in a 30% over all yield. $R_f = 0.25$ (PE/EtOAc 3:2); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.32 (s, 1H), 8.24 (d, *J* = 2.4 Hz, 1H), 7.35-7.28 (m, 5 H), 7.24 (br s, 1H), 7.13 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.00 (brs, 1H), 6.96 (d, *J* = 8.8 Hz, 1H), 6.42 (d, *J* = 16.8 Hz, 1H), 6.24 (dd, *J* = 16.8, 10.0 Hz, 1H), 5.79 (d, 10.0 Hz, 1H) 4.63 (d, *J* = 5.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For : C₁₇H₁₇N₂O₃⁺: 297.13; found: 297.24.




5-Acrylamido-2-hydroxy-*N***-(2-methylbenzyl)benzamide (RA10)** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA10** in a 45% over all yield. $R_f = 0.35$ (PE/EtOAc 3:2); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.31 (br s, 1H), 8.16 (d, *J* = 2.4 Hz, 1H), 7.28-7.14 (m, 5H), 6.96 (d, *J* = 9.2 Hz, 2H), 6.66 (br s, 1H), 6.40 (d, *J* = 16.8 Hz, 1H), 6.20 (dd, *J* = 16.8, 10.0 Hz), 5.77 (d, *J* = 10 Hz, 1H), 2.36-2.34 (m, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For : C₁₈H₁₉N₂O₃⁺: 311.14; found: 311.25.




RA11

5-Acrylamido-2-hydroxy-*N***-(3-methylbenzyl)benzamide (RA11)** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA11** in a 39% over all yield. $R_f = 0.25$ (PE/EtOAc 3:2); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.31 (br s, 1H), 8.22 (d, 3.2 Hz, 1H), 7.25-7.23 (m, 1H), 7.15-7.12 (m, 4H), 6.97 (d, J = 8.8 Hz, 1H), 6.73 (br s, 1H), 6.39 (d, J = 16.8 Hz, 1H), 6.43 (dd, J = 16.8, 10.0 Hz, 1H), 5.80 (d, J = 10.0 Hz, 1H), 4.6 (d, J = 5.2 Hz), 2.35 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For : C₁₈H₁₉N₂O₃⁺: 311.14; found: 311.27.




RA12

5-Acrylamido-2-hydroxy-*N***-(1-phenylethyl)benzamide (RA12)** Starting from compound **1a** and using procedure E followed by F and finally G yielded **RA12** in a 43% over all yield. $R_f = 0.35$ (PE/EtOAc 3:2); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.27 (br s, 1H), 8.19 (d, J = 2.4 Hz, 1H), 7.39-7.25 (m, 5H), 7.15 (dd, J = 8.8, 2.4 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.87 (br s, 1H), 6.43 (d, J = 16.8 Hz, 1H), 6.25 (dd, J = 16.8, 10.0 Hz, 1H), 5.78 (d, J = 10.0 Hz, 1H), 5.30 (quin, J = 7.2 Hz, 1H), 1.60 (d, J = 7.2 Hz, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For : C₁₈H₁₉N₂O₃⁺: 311.14; found: 311.26.




5-Acrylamido-2-hydroxy-*N***-(pyridin-2-ylmethyl)benzamide (RA13)** Starting from compound **1a** and using procedure E followed by F and finally G yielded **RA13** in a 25% over all yield. $R_f = 0.10$ (PE/EtOAc 1:1); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.23 (br s, 1H), 8.99 (br s, 1H), 8.21-8.18 (m, 1H), 8.12 (s, 1H), 7.70-7.63 (m, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.12 (dd, *J* = 15.8, 9.6 Hz, 1H), 6.89 (d, *J* = 9.6 Hz, 1H), 6.58 (d, *J* = 15.8 Hz, 1H), 6.42-6.22 (m, 1H), 6.01 (d, *J* = 9.6 Hz, 1H), 5.70-5.66 (m, 2H), 4.72-4.68 (m, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₆H₁₆N₃O₃⁺: 298.12; found: 298.21.




RA14

5-Acrylamido-2-hydroxy-*N***-(naphthalen-1-ylmethyl)benzamide (RA14)** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA14** in a 44% over all yield. $R_f = 0.25$ (PE/EtOAc 3:2); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 12.37 (br s, 1H), 8.05 (d, *J* = 2.8 Hz, 1H), 7.90-7.83 (m, 2H), 7.57-7.42 (m, 4 H), 7.18 (dd, *J* = 8.8, 2.8 Hz, 1H), 6.97 (d, *J* = 8.8 Hz, 1H), 6.80 (br s, 1H), 6.36 (d, *J* = 16.8 Hz, 1H), 6.18 (dd, *J* = 16.8, 10.0 Hz, 1H), 5.74 (d, *J* = 10.0 Hz, 1H), 5.09 (d, *J* = 5.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₁H₁₉N₂O₃⁺:347.14; found: 347.25.




RA15

5-Acrylamido-*N***-(furan-2-ylmethyl)-2-hydroxybenzamide (RA15)** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA15** in a 31% over all yield. $R_f = 0.25$ (PE/EtOAc 1:1); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 8.03 (d, J = 2.4 Hz, 1H), 7.56 (dd, J = 8.8, 2.4 Hz, 1H), 7.44 (s, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.44-6.31 (m, 4H), 5.76 (dd, J = 8.8, 2.4 Hz, 1H), 4.58 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{15}H_{15}N_2O_4^+$: 287.11; found: 287.22.




5-Acrylamido-2-hydroxy-*N***-(thiophen-2-ylmethyl)benzamide (RA16)** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA16** in a 44% over all yield. $R_f = 0.20$ (PE/EtOAc 1:1); ¹H NMR (400 MHz, CD₃OD, 23 °C) δ 8.03 (d, J = 2.4 Hz, 1H), 7.56 (dd, J = 8.4, 2.4 Hz, 1H), 7.30 (d, J = 4.8 Hz, 1H), 7.06 (d, J = 3.2 Hz, 1H), 6.96 (dd, J = 5.2, 3.6 Hz, 1H), 6.89 (d, J = 9.2 Hz, 1H), 6.44-6.32 (m, 2H), 5.75 (dd, J = 9.2, 2.4 Hz, 1H) 4.76 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₅H₁₆N₂O₃S⁺: 303.08; found: 303.18.




RA17

2-Hydroxy-*N***-(4-phenylbutan-2-yl)-5-propiolamidobenzamide (RA17):** Starting from compound **1a** and using procedure D followed by F and finally GI yielded RA17 in a 15% over all yield. $R_f = 0.40$ (PE/EtOAc 1:1); ¹H NMR (400 MHz, CDCl₃, 23 °C) δ 7.69 (d, J = 2.4 Hz, 1H), 7.54 (s, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.19 (d, J = 8.0 Hz, 1H), 2.95 (s, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{20}H_{21}N_2O_3^+$:337.16; found: 337.25.




RA18

2-methylphenethyl 5-acrylamido-2-hydroxybenzoate (RA18): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA18** in a 30% over all yield. $R_f = 0.3$ (PE/EtOAc 2:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.62 (dd, J = 8.8, 2.4 Hz, 1H), 7.27-7.18 (m, 4H), 6.99 (d, J = 8.8 Hz, 1H), 6.48 (d, J = 16.4 Hz, 1H), 6.26 (dd, J = 16.8, 10.4 Hz, 1H), 5.81 (d, J = 10.4 Hz, 1H), 4.54 (t, J = 7.6 Hz, 2H), 3.13 (t, J = 7.6 Hz, 2H), 2.42 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₂₀NO₄⁺: 326.16; found: 326.29.




3-phenylpropyl 5-acrylamido-2-hydroxybenzoate (RA19): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA19** in a 32% over all yield. $R_f = 0.31$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 7.99 (s, 1H), 7.67 (dd, J = 8.8, 2.4 Hz, 1H), 7.35-7.28 (m, 3H), 7.25-7.21 (m, 2H), 6.99 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 17.2 Hz, 1H), 6.27 (dd, J = 16.8, 10.4 Hz, 1H), 5.81 (d, J = 10.4 Hz, 1H), 4.39 (t, J = 6.4 Hz, 2H), 2.81 (t, J = 7.6 Hz, 2H), 2.19-2.12 (m, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₂₀NO₄⁺: 326.16; found: 326.28.




RA20

Phenethyl 5-acrylamido-2-hydroxybenzoate (RA20): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA20** in a 35% over all yield. $R_f = 0.31$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 7.62 (dd, J = 8.8, 2.4 Hz, 1H), 7.39-7.26 (m, 5H), 7.17 (s, 1H), 6.99 (d, J = 8.8 Hz, 1H), 6.48 (d, J = 16.8 Hz, 1H), 6.26 (dd, J = 16.8, 10.0 Hz, 1H), 5.82 (d, J = 10.0 Hz, 1H), 4.58 (t, J = 7.2 Hz, 2H), 3.13 (t, J = 7.6 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₈NO₄⁺⁺: 312.12; found: 312.25.




RA21

3-phenylbutyl 5-acrylamido-2-hydroxybenzoate (RA21): Starting from compund **1a** and using procedure A followed by F and finally G yielded **RA21** in a 30% over all yield. $R_f = 0.3$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.69 (dd, J = 8.8, 2.4 Hz, 1H), 7.36-7.32 (m, 2H), 7.25-7.21 (m, 3H), 7.17 (s, 1H), 6.98 (d, J = 8.8 Hz, 1H), 6.48 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.4 Hz, 1H), 5.82 (d, J = 10.0 Hz, 1H), 4.58 (td, J = 7.2, 1.6 Hz, 2H), 2.98-2.92 (m, 1H), 2.14-2.09 (m, 2H), 1.36 (d, J = 7.2 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{20}H_{22}NO_4^+$: 340.15; found: 340.29.




Benzyl 5-acrylamido-2-hydroxybenzoate (RA22): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA22** in a 40% over all yield. $R_f = 0.3$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.04 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 8.8, 2.0 Hz, 1H), 7.47-7.36 (m, 5H), 7.34 (s, 1H), 6.99 (d, J = 8.8 Hz, 1H), 6.44 (d, J = 17.2 Hz, 1H), 6.23 (dd, J = 16.8, 10.4 Hz, 1H), 5.77 (d, J = 10.0 Hz, 1H), 5.40 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{17}H_{16}NO_4^+$: 298.10; found: 298.23.




RA23

3,4-difluorobenzyl 5-acrylamido-2-hydroxybenzoate (RA23): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA23** in a 32% over all yield. $R_f = 0.37$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.5$ (s, 1H), 8.14 (d, J = 2.8 Hz, 1H), 7.66 (dd, J = 9.2, 2.8 Hz, 1H), 7.37-7.17 (m, 3H), 7.01 (d, J = 9.2 Hz, 1H), 6.46 (d, J = 17.2 Hz, 1H), 6.24 (dd, J = 16.8, 10.4 Hz, 1H), 5.81 (d, J = 10.0 Hz, 1H), 5.35 (s, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₇H₁₄F₂NO₄⁺: 334.08; found: 334.23.




RA24

3,4-dimethylbenzyl 5-acrylamido-2-hydroxybenzoate (RA24): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA24** in a 36% over all yield. $R_f = 0.4$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 8.8, 2.4 Hz, 1H), 7.45 (s, 1H), 7.21-7.16 (m, 3H), 6.96 (d, J = 8.8 Hz, 1H), 6.43 (d, J = 16.8 Hz, 1H), 6.22 (dd, J = 17.2, 10.4 Hz, 1H), 5.76 (d, J = 10.4 Hz, 1H), 5.32 (s, 2H), 2.30 (s, 3H), 2.29 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₂₀NO₄⁺: 326.13; found: 326.29.




2-phenylbutyl 5-acrylamido-2-hydroxybenzoate (RA25): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA25** in a 27 % over all yield. $R_f = 0.41$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 7.97 (d, J = 2.4 Hz, 1H), 7.67 (dd, J = 8.8, 2.0 Hz, 1H), 7.38-7.25 (m, 7H), 6.97 (d, J = 9.2 Hz, 1H), 6.47 (d, J = 16.8 Hz, 1H), 6.26 (dd, J = 16.8, 10.4 Hz, 1H), 5.81 (d, J = 10.0 Hz, 1H), 4.49 (d, J = 6.8 Hz, 2H), 3.10-3.02 (m, 1H), 1.96-1.89 (m, 1H), 1.79-1.71 (m, 1H), 0.92 (t, J = 7.6 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{20}H_{22}NO_4^+$: 340.15; found: 340.28.




RA26

3-methylphenethyl 5-acrylamido-2-hydroxybenzoate (RA26): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA26** in a 32% over all yield. $R_f = 0.4$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.8, 2.0 Hz, 1H), 7.26-7.21 (m, 1H), 7.13-7.10 (m, 3H), 6.99 (d, J = 8.8 Hz, 1H), 6.48 (d, J = 16.8 Hz, 1H), 6.26 (dd, J = 16.8, 10.4 Hz, 1H), 5.82 (d, J = 10.0 Hz, 1H), 4.56 (t, J = 7.2 Hz, 2H), 3.10 (t, J = 7.2 Hz, 2H), 2.37 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₂₀NO₄⁺: 326.13; found: 326.29.




RA27

[1,1'-biphenyl]-4-ylmethyl 5-acrylamido-2-hydroxybenzoate (RA27): Starting from compund **1a** and using procedure A followed by F and finally G yielded **RA27** in a 38% over all yield. $R_f = 0.41$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.66$ (s, 1H), 8.09 (d, J = 2.8 Hz, 1H), 7.72 (d, J = 9.2 Hz, 1H), 7.65-7.62 (m, 4H), 7.60-7.49 (m, 4H), 7.33-7.32 (m, 1H), 7.00 (d, J = 9.2 Hz, 1H), 6.44 (d, J = 16.8 Hz, 1H), 6.26 (dd, J = 16.8, 10.4 Hz, 1H), 5.78(d, J = 10.4 Hz, 1H), 5.44 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₃H₂₀NO₄⁺: 374.13; found: 374.29.




(9*H*-fluoren-9-yl)methyl 5-acrylamido-2-hydroxybenzoate (RA28): Starting from compound 1a and using procedure A followed by F and finally G yielded RA28 in a 25% over all yield. $R_f = 0.36$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.66$ (s, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.94-7.90 (m, 3H), 7.87-7.77 (m, 2H), 7.68-7.48 (m, 4H), 7.26 (s, 1H), 6.98 (d, J = 8.8 Hz, 1H), 6.36 (d, J = 16.8 Hz, 1H), 6.09 (dd, J = 16.8, 10.0 Hz, 1H), 5.83 (s, 2H), 5.69(d, J = 10.4 Hz, 1H), 5.33(s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₄H₂₀NO₄⁺: 386.13; found: 386.28.




RA29

2-(thiophen-2-yl)ethyl 5-acrylamido-2-hydroxybenzoate (RA29): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA29** in a 28% over all yield. $R_f = 0.36(PE/EtOAc 3:2)$; ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.66$ (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 7.66 (dd, J = 9.2, 2.0 Hz, 1H), 2.6 (s, 1H), 7.20 (dd, J = 5.6, 1.2 Hz, 1H), 6.99-6.94 (m, 3H), 6.46 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 17.2, 10.4 Hz, 1H), 5.79(d, J = 10.4 Hz, 1H), 4.57 (t, J = 7.2 Hz, 2H), 3.32 (t, J = 7.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₆H₁₆NO₄S⁺: 318.08; found: 318.21.




RA30

5-acrylamido-*N*-(**3-fluorophenethyl**)-**2-hydroxybenzamide (RA30):** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA30** in a 35% over all yield. $R_f = 0.34$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 12.2$ (s, 1H), 8.21 (s, 1H), 7.33-7.29 (m, 1H), 7.18-7.04 (m, 3H), 6.98 (d, J = 16.8 Hz, 1H), 6.70 (s, 1H), 6.46 (d, J = 16.8 Hz, 1H), 6.25 (dd, J = 16.8, 10.0 Hz, 1H), 5.83 (d, J = 10.4 Hz, 1H), 3.71 (t, J = 7.2 Hz, 2H), 3.10 (t, J = 7.2 Hz, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₈FN₂O₃⁺: 329.13; found: 329.25.




5-acrylamido-2-hydroxy-*N***-(4-methylbenzyl)benzamide (RA31):** Starting from compound **1a** and using procedure D followed by F and finally G yielded **RA31** in a 30% over all yield. $R_f = 0.38$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 12.3$ (s, 1H), 8.21 (d, J = 2.8 Hz, 1H), 7.30-7.14 (m, 5H), 6.98 (d, J = 8.8 Hz, 1H), 6.43 (d, J = 16.8 Hz, 1H), 6.23 (dd, J = 16.8, 10.0 Hz, 1H), 5.82 (d, J = 10.0 Hz, 1H), 4.61 (d, J = 5.6 Hz, 2H), 2.39 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₉N₂O₃⁺: 311.14; found: 311.27.




RA32

2,3-dihydro-1*H***-inden-1-yl 5-acrylamido-2-hydroxybenzoate RA32:** Starting from compound 1a and using procedure B followed by F and finally G yielded **RA32** in a 26% over all yield. $R_f = 0.53$ (PE/EtOAc 7:3);¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.8$ (s, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.76 (dd, J = 8.4, 2.0 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.38-7.33 (m, 2H), 7.27-7.25 (m, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.49 (dd, J = 6.4, 3.2 Hz, 1H), 6.39 (d, J = 16.8 Hz, 1H), 6.18 (dd, J = 17.2, 10.0 Hz, 1H), 5.73 (d, J = 10.0 Hz, 1H), 3.25-3.17 (m, 1H), 3.01-2.93 (m, 1H), 2.67-2.58 (m, 1H), 2.32-2.24 (m, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₁₇NO₄⁺: 324.12; found: 324.26.




RA33

4-phenylbutan-2-yl 5-acrylamido-2-hydroxybenzoate RA33: Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA33** in a 28% over all yield. $R_f = 0.32$ (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.8$ (s, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.69 (dd, J = 8.8, 2.8 Hz, 1H), 7.45 (s, 1H), 7.31-7.20 (m, 5H), 6.98 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.4 Hz, 1H), 5.79 (d, J = 10.0 Hz, 1H), 5.25-5.21 (m, 1H), 2.77-2.72 (m, 2H), 2.19-2.08 (m, 1H), 2.01-1.95 (m, 1H), 1.41 (d, J = 6.4 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{20}H_{22}NO_4^+$: 340.15; found: 340.28.




1-phenylethyl 5-acrylamido-2-hydroxybenzoate (RA34): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA34** in a 28% over all yield. $R_f = 0.45$ (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.69 (dd, J = 8.8, 2.8 Hz, 1H), 7.51 (s, 1H), 7.46-7.32 (m, 5H), 6.96 (d, J = 9.2 Hz, 1H), 6.46 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 17.2, 10.4 Hz, 1H), 6.16 (q, J = 6.8 Hz, 1H), 5.79 (d, J = 10.0 Hz, 1H), 1.71 (d, J = 6.8 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₈NO₄⁺: 312.12; found: 312.26.



RA35

2,3-dimethylphenyl 5-acrylamido-2-hydroxybenzoate (RA35): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA35** in a 22% over all yield. $R_f = 0.22$ (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.46$ (s, 1H), 8.39 (d, J = 2.4 Hz, 1H), 7.75 (dd, J = 8.8, 2.4 Hz, 1H), 7.48 (s, 1H), 7.21-7.13 (m, 2H), 7.05 (d, J = 9.2 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.47 (d, J = 17.2 Hz, 1H), 6.27 (dd, J = 17.2, 10.4 Hz, 1H), 5.80 (d, J = 10.0 Hz, 1H), 2.35 (s, 3H), 2.14 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₇NO₄⁺: 312.12; found: 312.26.




RA36

Naphthalen-1-yl 5-acrylamido-2-hydroxybenzoate (RA36): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA36** in a 24% over all yield. $R_f = 0.18$ (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.3$ (s, 1H), 8.53 (d, J = 2.0 Hz, 1H), 7.95(d, J = 1.6, Hz, 1H), 7.89 (dd, J = 18.0, 10.0 Hz, 2H), 7.79 (dd, J = 8.8, 2.4 Hz, 1H), 7.64 (s, 1H), 7.58-7.51 (m, 4H), 7.35 (d, J = 7.2 Hz, 1H), 7.06 (d, J = 9.2 Hz, 1H), 6.47 (d, J = 16.8 Hz, 1H), 6.28 (dd, J = 16.8, 10.4 Hz, 1H), 5.78 (d, J = 10.4 Hz, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₀H₁₅NO₄⁺: 334.10 found: 334.21.




3,4-dimethylbenzyl 5-(2-chloroacetamido)-2-hydroxybenzoate (RA37): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA37** in a 30% over all yield. $R_f = 0.45$ (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.61 (s, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.72 (dd, J = 8.8, 2.8 Hz, 2H), 7.24-7.20 (m, 3H), 7.01 (d, J = 8.8 Hz, 1H), 5.35 (s, 2H), 4.23 (s, 2H), 2.32 (s, 3H), 2.31 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₉ClNO₄⁺: 348.08 found: 348.18.




RA38

Naphthalen-1-ylmethyl 5-acrylamido-2-hydroxybenzoate (RA38): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA38** in a 32% over all yield. $R_f = 0.47$ (PE/EtOAc 3:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.44 (d, J = 8.0 Hz, 1H), 7.91 (t, J = 8.0 Hz, 2H), 7.81-7.75 (m, 2H), 7.62-7.47 (m, 4H), 7.35 (s, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.35 (d, J = 17.2 Hz, 1H), 6.07 (dd, J = 17.2, 10.4 Hz, 1H), 5.82 (s, 2H), 5.67 (d, J = 10.0 Hz, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₁H₁₈NO₄⁺: 348.08 found: 348.18.




RA39

2-(4-methylthiazol-5-yl) ethyl 5-acrylamido-2-hydroxybenzoate (RA39): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA39** in a 35% over all yield. $R_f = 0.15$ (PE/EtOAc 2:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.5$ (s, 1H), 8.63 (s, 1H), 8.14 (d, J = 1.6 Hz, 1H), 7.83 (s, 1H), 7.58 (dd, J = 8.8, 2.0 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.46 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.0 Hz, 1H), 5.77 (d, J = 10.0 Hz, 1H), 4.51 (t, J = 6.8 Hz, 2H), 3.26 (t, J = 6.8 Hz, 2H), 2.46 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₆H₁₇N₂O₄S⁺: 333.09 found: 333.18.



Pyridin-2-ylmethyl 5-acrylamido-2-hydroxybenzoate (RA40): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA40** in a 30% over all yield. $R_f = 0.21$ (PE/EtOAc 2:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.5$ (s, 1H), 8.65 (d, J = 4.0 Hz, 1H), 8.14 (s, 1H), 7.79-7.72 (m, 2H), 7.46 (d, J = 7.6, Hz, 1H), 7.39 (s,1H), 7.30 (s,1H), 7.01 (d, J = 8.8 Hz, 1H), 6.45 (d, J = 16.8, Hz, 1H), 5.79 (d, J = 10.0 Hz, 1H), 5.53 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₆H₁₅N₂O₄⁺: 299.10 found: 299.21.




RA41


Naphthalen-1-ylmethyl 5-(2-chloroacetamido)-2-hydroxybenzoate (RA41): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA41** in a 32% over all yield. $R_f = 0.41$ (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.11 (d, J = 7.6 Hz, 1H), 8.09 (s, 1H), 7.96-7.92 (m, 2H), 7.84 (d, J = 2.8, Hz, 1H), 7.72 (dd, J = 8.8, 2.8 Hz, 1H), 7.67-7.51 (m, 4H), 7.02 (d, J = 9.2, Hz, 1H), 5.87 (s, 2H), 4.15 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₀H₁₇ClNO₄⁺: 371.07 found: 371.19.



2-(4-methylthiazol-5-yl)ethyl 5-(2-chloroacetamido)-2-hydroxybenzoate (RA42): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA42** in a 30% over all yield. $R_f = 0.11$ (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.65 (s, 1H), 8.23 (s, 1H), 8.10 (d, J = 2.8 7.58 (dd, J = 8.8, 2.4 Hz, 1H), 7.01 (d, J = 8.8, Hz, 1H), 4.54 (t, J = 6.4 Hz, 1H), 4.22 (s, 2H), 3.29 (t, J = 6.8 Hz, 1H), 2.48 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{15}H_{16}CIN_2O_4S^+$: 355.05 found: 355.17.



3-methylphenethyl 5-(2-chloroacetamido)-2-hydroxybenzoate (RA43): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA43** in a 36% over all yield. $R_f = 0.5$ (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.17 (s, 1H), 8.06 (d, J = 2.8, Hz, 1H), 7.64 (dd, J = 8.8, 2.8 Hz, 1H), 7.25(d, J = 6.4, Hz, 1H), 7.13-7.09 (m, 3H), 7.01(d, J = 8.8, Hz, 1H), 4.56 (t, J = 7.6 Hz, 1H), 4.24 (s, 2H), 3.09 (t, J = 7.6 Hz, 1H), 2.83 (s, 3H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₉CINO₄⁺: 348.09 found: 348.79.




RA44


1-(pyridin-2-yl)ethyl 5-acrylamido-2-hydroxybenzoate (RA44): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA44** in a 30% over all yield. $R_f = 0.31$ (PE/EtOAc 2:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.63 (d, J = 4.4, Hz, 1H), 8.15 (d, J = 2.4, Hz, 1H), 7.77-7.72 (m, 2H), 7.53 (s, 1H), 7.44 (d, J = 8.0, Hz, 1H), 7.27-7.25 (m, 1H), 6.97(d, J = 8.8, Hz, 1H), 6.46 (d, J = 16.8 Hz, 1H), 6.30-6.18 (m, 2H), 5.80 (d, J = 11.2 Hz, 1H), 1.77 (d, J = 6.8 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{17}H_{17}N_2O_4^{+1}$: 313.11 found: 313.22.



(*Z*)-1-(pyridin-2-yl)ethyl 5-(3-chloroacrylamido)-2-hydroxybenzoate (RA45): Starting from compound 1a and using procedure B followed by F and finally E yielded RA45 in a 18% over all yield. $R_f = 0.24$ (PE/EtOAc 4:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.12 (d, J = 2.4, Hz, 1H), 7.93 (s, 1H), 7.68 (dd, J = 9.2, 2.8, Hz, 1H), 7.48-7.33 (m, 5H), 6.99 (d, J = 8.8, Hz, 1H), 6.66(d, J = 8.8, Hz, 1H), 6.35 (d, J = 8.8 Hz, 1H), 6.17 (q, J = 6.8 Hz, 1H), 1.73 (d, J = 6.4 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₇H₁₆ClN₂O₄⁺: 347.08 found: 347.17.




2-(4-methylthiazol-5-yl) ethyl 2-hydroxy-5-propiolamidobenzoate (RA46): Starting from compound **1a** and using procedure B followed by F and finally GI yielded **RA46** in a 25% over all yield. $R_f = 0.16$ (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.66 (s, 1H), 8.10 (d, J = 2.8, Hz, 1H), 7.79 (s, 1H), 7.56 (dd, J = 8.8, 2.8 Hz, 1H), 6.99(d, J = 8.8, Hz, 1H), 4.54 (t, J = 6.4 Hz, 1H), 3.28 (t, J = 7.6 Hz, 1H), 2.96 (s, 1H), 2.47 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₆H₁₅N₂O₄S⁺: 331.107 found: 331.20.




RA47

Naphthalen-2-yl 5-acrylamido-2-hydroxybenzoate (RA47): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA47** in a 28% over all yield. $R_f = 0.19$ (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.4$ (s, 1H), 8.46 (d, J = 2.8, Hz, 1H), 7.96-7.86 (m, 3H), 7.75 (dd, J = 8.8, 2.0 Hz, 1H), 7.70 (d, J = 2.0, Hz, 1H), 7.58-7.52 (m, 2H), 7.37 (dd, J = 8.8, 2.4 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 6.50 (d, J = 16.8 Hz, 1H), 6.29 (dd, J = 16.8, 10.0 Hz, 1H), 5.83 (d, J = 10.0 Hz, 1H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₀H₁₆NO₄⁺: 334.10 found: 334.22.




RA48

2-(thiophen-2-yl)ethyl 5-acrylamido-2-hydroxybenzoate (RA48): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA48** in a 40% over all yield. $R_f = 0.46$ (PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.46 (d, J = 2.8, Hz, 1H), 7.61 (dd, J = 8.8, 2.4 Hz, 1H), 7.45 (s, 1H), 7.33-7.31 (m,1H), 7.12 (d, J = 2.0 Hz, 1H), 7.05 (dd, J = 4.0, 1.2 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H), 6.47 (dd, J = 16.8, 0.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.0 Hz, 1H), 5.79 (dd, J = 10.0, 0.8 Hz, 1H),4.56 (t, J = 6.8 Hz, 2H), 3.14 (t, J = 6.8 Hz, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₆H₁₆NO₄S⁺: 317.07 found: 318.20.




2,2-diphenylethyl 5-acrylamido-2-hydroxybenzoate (RA49): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA49** in a 40% over all yield. $R_f = 0.48$ (PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.5$ (s, 1H), 7.81 (s, 1H), 7.71 (d, J = 9.2, Hz, 1H), 7.38-7.25 (m,11H), 6.96 (d, J = 9.2 Hz, 1H), 6.45 (d, J = 16.0 Hz, 1H), 6.27 (dd, J = 16.8, 10.0 Hz, 1H),5.79 (d, J = 10.0 Hz, 1H), 4.91 (d, J = 7.6 Hz, 1H), 4.56 (t, J = 7.2, Hz, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: $C_{24}H_{22}NO_4^+$: 387.14 found: 388.27.



KA5U

2,3-dihydro-1*H***-inden-2-yl 5-acrylamido-2-hydroxybenzoate (RA50):** Starting from compound **1a** and using procedure E followed by F and finally G yielded **RA50** in a 15% over all yield. $R_f = 0.44$ (PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 7.82 (s, 1H), 7.80 (s, 1H), 7.32-7.24 (m, 4H), 7.21 (s, 1H), 7.00 (d, J = 9.2 Hz, 1H), 6.43 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.0 Hz, 1H), 5.84- 5.83 (m, 1H), 3.48 (dd, J = 17.2, 6.8 Hz, 2H), 3.23 (dd, J = 17.2, 3.2 Hz, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₁₈NO₄⁺: 323.11 found: 324.21.




RA51


3,4-difluorophenyl 5-acrylamido-2-hydroxybenzoate (RA51): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA51** in a 10% over all yield. $R_f = 0.37$ (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.0$ (s, 1H), 8.42 (d, J = 2.4 Hz, 1H), 7.73 (dd, J = 9.2 2.0 Hz, 1H), 7.19-7.14 (m, 2H), 7.07-7.03 (m, 2H), 6.47 (d, J = 16.0 Hz, 1H), 6.28 (dd, J = 16.8, 10.0 Hz, 1H), 5.79 (d, J = 10.0 Hz, 1H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₆H₁₂F₂NO₄⁺: 319.06 found: 320.21.



Cinnamyl 5-acrylamido-2-hydroxybenzoate (RA52): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA52** in a 40% over all yield. $R_f = 0.41$ (PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.10 (d, J = 2.0 1H), 7.62 (dd, J = 8.8, 2.4 Hz, 2H), 7.41 (d, J = 6.8 Hz, 1H), 7.33 (t, J = 5.2 Hz, 1H), 7.26-7.24 (m, 1H), 7.19-7.16 (m, 1H), 6.95 (d, J = 9.2 Hz, 1H), 6.73 (d, J = 16.0 Hz, 1H), 6.39- 6.32 (m, 2H), 5.74 (d, J = 10.4 Hz, 1H), 4.99 (d, J = 15.2 Hz, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₉H₁₈NO₄⁺: 323.11 found: 324.23.




3-(trifluoromethyl)phenyl 5-acrylamido-2-hydroxybenzoate (RA53): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA53** in a 10% over all yield. R*f* = 0.48 x(PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) δ = 10.2 (s, 1H), 8.45 (d, *J* = 2.4 Hz, 1H), 7.68 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.61 (d, *J* = 5.4 Hz, 1H), 7.52 (s, 1H), 7.46-7.43 (m, 2H), 7.05 (d, *J* = 9.2 Hz, 1H), 6.49 (d, *J* = 16.8 Hz, 1H), 6.28 (dd, *J* = 16.8, 10.4 Hz, 1H), 5.82 (d, *J* = 10.4 Hz, 1H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₇H₁₃F₃NO₄⁺: 351.07 found: 352.18.




RA54

Phenyl 5-acrylamido-2-hydroxybenzoate(RA54): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA54** in a 10% over all yield. Rf = 0.33 (PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.4$ (s, 1H), 8.38 (s, 1H), 7.74-7.73 (m, 1H), 7.51-7.46(m, 2H), 7.36-7.32 (m, 2H), 7.24-7.22 (m, 2H), 7.08-7.05 (m, 1H), 6.49 (d, J = 16.8 Hz, 1H), 6.31-6.24 (m, 1H), 5.83 (dd, J = 9.2, 2.8 Hz, 1H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₆H₁₄NO₄⁺: 283.08 found: 284.20.




1-phenylpropan-2-yl 5-acrylamido-2-hydroxybenzoate (RA55): Starting from compound **1a** and using procedure C followed by F and finally G yielded **RA55** in 40% over all yield. Rf = 0.42 (PE/EtOAc 6:4); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.15 (s, 1H), 7.62 (dd, J = 8.4, 2.4 Hz, 1H), 7.47 (s, 1H), 7.34-7.23(m, 5H), 6.96 (dd, J = 8.8, 2.8 Hz, 1H), 6.48 (d, J = 16.8 Hz, 1H), 6.28 (dd, J = 16.8, 10.4 Hz, 1H), 5.80 (d, J = 10.0 Hz, 1H), 5.44-5.38 (m, 1H), 3.14-3.09 (m, 1H), 2.94-2.89 (m, 1H), 1.38 (d, J = 6.4 Hz, 3H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For C₁₉H₂₀NO₄⁺: 325.13 found: 326.27.




RA56

3-(benzyloxy)benzyl 5-acrylamido-2-hydroxybenzoate (RA56): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA56** in 40% over all yield. Rf = 0.58 (PE/EtOAc 8:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 8.04 (d, J = 2.4 Hz, 1H), 7.73 (dd, J = 8.8, 2.4 Hz, 1H), 7.47-7.30 (m, 7H), 7.09-6.98 (m, 4H), 6.42 (d, J = 16.8 Hz, 1H), 6.21 (dd, J = 16.8, 10.4 Hz, 1H), 5.77 (d, J = 10.4 Hz, 1H), 5.37 (s, 2H), 5.12 (s, 1H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₄H₂₂NO₅⁺: 403.13 found: 403.91.




RA57

3-(benzyloxy)benzyl 5-(2-chloroacetamido)-2-hydroxybenzoate(RA57): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA57** in a 40% over all yield. R*f* = 0.44 (PE/EtOAc 8:2); ¹H (CDCl₃, 400 MHz, 25 °C) δ = 10.6 (s, 1H), 8.16 (s, 1H), 7.99 (d, *J* = 2.8 Hz, 1H), 7.70 (dd, *J* = 9.2, 2.8 Hz, 1H), 7.48-7.33 (m, 6H), 7.10-6.99 (m, 4H), 5.39 (s, 2H), 5.12 (s, 2H), 4.20 (s, 2H). LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₃H₂₁ClNO₅⁺: 425.10 found: 426.12.




3-(benzyloxy)benzyl 2-hydroxy-5-propiolamidobenzoate (RA58): Starting from compound **1a** and using procedure B followed by F and finally GI yielded **RA58** in a 10% over all yield. Rf = 0.45 (PE/EtOAc 1:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 7.97 (d, J = 2.8 Hz, 1H), 7.48 (dd, J = 9.2, 2.8 Hz, 1H), 7.41-7.35 (m, 6H), 7.09-7.00 (m, 4H), 5.38 (s, 2H), 5.13 (s, 2H), 2.95 (s, 1H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₄H₂₀NO₅⁺: 401.12 found: 402.19.




RA59

4-(benzyloxy)benzyl 5-acrylamido-2-hydroxybenzoate (RA59): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA59** in a 40% over all yield. R*f* = 0.61 (PE/EtOAc 8:2); ¹H (CDCl₃, 400 MHz, 25 °C) δ = 10.6 (s, 1H), 8.00 (d, *J* = 2.0 Hz, 1H), 7.73 (dd, *J* = 9.2, 2.8 Hz, 1H), 7.47-7.38 (m, 7H), 7.18 (s, 1H), 7.03-6.98 (m, 3H), 6.44 (d, *J* = 16.8 Hz, 1H), 6.20 (dd, *J* = 16.8, 10.4 Hz, 1H), 5.79 (d, *J* = 10.4 Hz, 1H), 5.34 (s, 2H), 5.11 (s, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₄H₂₂NO₅⁺: 403.14 found: 403.76.




RA60

4-(benzyloxy)benzyl 5-(2-chloroacetamido)-2-hydroxybenzoate (RA60): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA60** in a 40% over all yield. R*f* = 0.50 (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) δ = 10.7 (s, 1H), 8.14 (s, 1H), 7.94 (d, *J* = 2.8 Hz, 1H), 7.70 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.47-7.34 (m, 7H), 7.04-7.01 (m, 3H), 5.35 (s, 2H), 5.11 (s, 2H), 4.21 (s, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₃H₂₁ClNO₅⁺: 425.10 found: 426.12.




2-(benzyloxy)benzyl 5-acrylamido-2-hydroxybenzoate (RA61): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA61** in a 40% over all yield. Rf = 0.61 (PE/EtOAc 8:2); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.6$ (s, 1H), 7.89 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.45-7.31 (m, 7H), 7.16 (m, 1H), 7.04-6.98 (m, 3H), 6.43 (d, J = 16.8 Hz, 1H), 6.27 (dd, J = 16.8, 10.0 Hz, 1H), 5.77 (d, J = 10.4 Hz, 1H), 5.52 (s, 2H), 5.16 (s, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₄H₂₂NO₅⁺: 403.14 found: 403.76.




RA62

2-(benzyloxy)benzyl 5-(2-chloroacetamido)-2-hydroxybenzoate (RA62): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA62** in a 40% over all yield. R*f* = 0.50 (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) δ = 10.7 (s, 1H), 8.13 (s, 1H), 7.90 (d, *J* = 2.4 Hz, 1H), 7.75 (dd, *J* = 9.2, 2.8 Hz, 1H), 7.46-7.33 (m, 7H), 7.05-7.01 (m, 3H), 5.53 (s, 2H), 5.17 (s, 2H), 4.19 (s, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₂₃H₂₁ClNO₅⁺: 425.10 found: 426.12.




RA63

3-acrylamido-N-benzyl-4,6-dihydroxy-2-methylbenzamide (RA63): Starting from compound **1b** and using procedure J, followed by G, K, and finally D(with HOBt & NMM – 3equiv.) yielded **RA63** in a 24% over all yield. R*f* = 0.2 (PE/EtOAc 1:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 7.44 (d, *J* = 7.2 Hz, 2H), 7.34 (t, *J* = 7.6 Hz, 2H), 7.26 (t, *J* = 7.6 Hz, 1H), 6.51 (dd, *J* = 16.8, 10.4 Hz, 1H), 6.35 (m, 1H), 6.34 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.78 (dd, *J* = 10.4, 1.6 Hz, 1H), 4.57 (s, 2H), 2.10 (s, 2H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₉N₂O₄⁺: 327.13 found: 327.20




Butyl 3-acrylamido-4,6-dihydroxy-2-methylbenzoate (RA64): Starting from compound **1b** and using procedure J followed by G, K and finally B yielded **RA64** in a 22% over all yield. R*f* = 0.28(PE/EtOAc 1:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 6.51 (dd, *J* = 16.8, 10.0 Hz, 1H), 6.37 (d, *J* = 1.2 Hz, 1H), 6.33 (s, 1H), 5.80 (dd, *J* = 10.0, 1.2 Hz, 1H), 4.37 (t, *J* = 6.4 Hz, 2H), 2.36 (s, 3H), 1.81-1.74 (m, 2H), 1.54-1.46 (m, 2H), 1.01 (t, *J* = 7.6 Hz, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₅H₂₀NO₅⁺: 294.13 found: 294.21.




RA65

Benzyl 3-acrylamido-4,6-dihydroxy-2-methylbenzoate (RA65): Starting from compound **1b** and using procedure J followed by G, K and finally B yielded **RA65** in a 24% over all yield. R*f* = 0.18(PE/EtOAc 1:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 7.48 (d, *J* = 6.4 Hz, 2H), 7.42-7.35 (m, 3H), 6.50 (dd, *J* = 17.2, 10.0 Hz, 1H), 6.34 (s, 1H), 6.33 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.77 (dd, *J* = 10.4, 1.6 Hz, 1H), 5.40 (s, 2H), 2.36 (m, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₈NO₅⁺: 328.11 found: 328.16.




RA66

Phenyl 3-acrylamido-4,6-dihydroxy-2-methylbenzoate (RA66): Starting from compound **1b** and using procedure J followed by G, K and finally C yielded **RA66** in a 18 % over all yield. R*f* = 0.31(PE/EtOAc 2:3); ¹H (MeOD, 400 MHz, 25 °C) δ = 7.49-7.45 (m, 2H), 7.33 (t, *J* = 6.8 Hz, 1H), 7.24 (d, *J* = 7.6 Hz, 1H), 6.55 (dd, *J* = 17.2, 10.0 Hz, 1H), 6.40 (s, 1H), 6.37 (dd, *J* = 17.2, 1.6 Hz, 1H), 5.81 (dd, *J* = 10.8, 2.0 Hz, 1H), 2.18 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₇H₁₆NO₅⁺: 314.10 found: 314.13.




3-acrylamido-4,6-dihydroxy-2-methyl-N-phenylbenzamide (RA67): Starting from compound **1b** and using procedure J followed by G, K and finally D(with HOBt & NMM -3 equiv.) yielded **RA67** in a 20 % over all yield. R*f* = 0.24 (DCM/MeOH 9:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 7.67 (d, *J* = 7.6 Hz, 2H), 7.35 (t, *J* = 8.0 Hz, 2H), 7.13 (t, *J* = 7.6 Hz, 1H), 6.53 (dd, *J* = 17.2, 10.4 Hz, 1H), 6.39 (s, 1H), 6.34 (d, *J* = .6 Hz, 1H), 5.79 (dd, *J* = 10.8, 1.6 Hz, 1H), 2.18 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₇H₁₇N₂O₄⁺: 312.11 found: 313.22.




RA68

3-acrylamido-N-(benzo[d][1,3]dioxol-5-yl)-4,6-dihydroxy-2-methyl Benzamide (RA68): Starting from compound **1b** and using procedure J followed by G, K and finally D (with HOBt & NMM – 3equiv.) yielded **RA68** in a 21 % over all yield. R*f* = 0.22 (DCM/MeOH 9:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 7.37 (d, *J* = 1.6 Hz, 1H), 7.02 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.80 (d, *J* = 8.4 Hz, 1H), 6.53 (dd, *J* = 17.2, 10.0 Hz, 1H), 6.37 (t, *J* = .15.6 Hz, 1H), 5.96(s, 2H), 5.79 (dd, *J* = 10.0, 1.2 Hz, 1H), 2.17 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₇N₂O₆⁺: 357.10 found: 357.14.




RA69

4-nitrobenzyl 3-acrylamido-4,6-dihydroxy-2-methylbenzoate (RA69): Starting from compound **1b** and using procedure J followed by G, K and finally B yielded **RA69** in a 21% over all yield. R*f* = 0.2 (PE/EtOAc 1:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 8.28 (d, *J* = 8.8 Hz, 2H), 7.73 (d, *J* = 8.8 Hz, 1H), 6.51 (dd, *J* = 16.8, 10.4 Hz, 1H), 6.34(s, 1H), 6.32 (dd, *J* = .17.2, 1.6 Hz, 1H), 5.78 (dd, *J* = 10.4, 2.0 Hz, 1H), 5.53 (s, 2H), 2.33 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₈H₁₇N₂O₇⁺: 373.10 found: 373.14.




4-methoxybenzyl 3-acrylamido-4,6-dihydroxy-2-methylbenzoate (RA70): Starting from compound **1b** and using procedure J followed by G, K and finally B yielded **RA70** in a 24% over all yield. R*f* = 0.2(PE/EtOAc 1:1); ¹H (MeOD, 400 MHz, 25 °C) δ = 7.41 (d, *J* = 8.4 Hz, 2H), 6.95 (dd, *J* = 6.8, 2.0 Hz, 2H), 6.48 (dd, *J* = .16.8, 10.4 Hz, 1H), 6.33(s, 1H), 6.32 (dd, *J* = .17.2, 1.6 Hz, 1H), 5.77 (dd, *J* = 10.0, 1.6 Hz, 1H), 5.33 (s, 2H), 3.82 (s, 3H), 2.28 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₉H₂₀NO₆⁺: 358.12 found: 358.19.




RA71

Furan-2-ylmethyl 5-acrylamido-2-hydroxybenzoate (RA71): Starting from compound **1a** and using procedure A followed by F and finally G yielded **RA71** in a 40% over all yield. Rf = 0.22 (PE/EtOAc 7:3); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.5$ (s, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.74 (dd, J = 9.2, 2.8 Hz, 1H), 7.48 (s, 1H), 6.99 (d, J = .9.2 Hz, 1H), 6.54 (d, J = 3.2 Hz, 1H), 6.46 (s, 1H), 6.42 (s, 1H), 6.22 (dd, J = 16.0, 10.4 Hz, 1H), 5.78 (d, J = 10.4 Hz, 1H), 5.36 (s, 2H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₅H₁₄NO₅⁺: 287.07 found: 288.21.




RA72

3-acrylamido-4,6-dihydroxy-2-methyl-N-(2-(thiophen-2-yl)ethyl)benzamide) (RA72): Starting from compound **1b** and using procedure J followed by G, K and finally D (with HOBt & NMM-3equiv.) yielded RA72 in a 24% over all yield. Rf = 0.23 (PE/EtOAc 2:3); ¹H (MeOD, 400 MHz, 25 °C) $\delta = 7.24-7.22$ (m, 1H), 6.95-6.93 (m, 2H), 6.51 (dd, J = 17.2, 10.0 Hz, 1H), 6.38-6.32 (m, 2H), 5.78 (dd, J = .10.4, 2.4 Hz, 1H), 3.63 (t, J = 7.2 Hz, 1H), 3.14 (t, J = 7.2 Hz, 1H), 2.05 (s, 3H) ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₇H₁₉N₂O₄S⁺: 347.10 found: 347.15.




RA73

Butyl 5-acrylamido-2-hydroxybenzoate (RA73): Starting from compound **1a** and using procedure B followed by F and finally G yielded **RA73** in a 35% over all yield. Rf = 0.2 (PE/EtOAc 4:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.66 (dd, J = 8.4, 2.0 Hz, 1H), 7.24 (s, 1H), 6.99 (d, J = 9.2 Hz, 1H), 6.47 (d, J = 16.4 Hz, 1H), 6.26(dd, J = 17.2, 10.4 Hz, 1H), 5.80 (d, J = .10.4 Hz, 1H), 4.38 (t, J = 6.4 Hz, 2H),1.81-1.76 (m, 2H), 1.53-1.45 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H)ppm; LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₄H₁₈NO₄⁺: 264.12 found: 264.19.




RA74

(E)-butyl 5-(but-2-enamido)-2-hydroxybenzoate (RA74): Starting from compound 2a and using procedure B followed by F and finally G yielded RA74 in a 30% over all yield. Rf = 0.2 (PE/EtOAc 4:1); ¹H (CDCl₃, 400 MHz, 25 °C) $\delta = 10.7$ (s, 1H), 8.05 (s, 1H), 7.99(d, J = 2.8 Hz, 1H), 7.58 (dd, J = 9.2, 2.8 Hz, 1H), 7.07-7.02 (m, 1H), 7.01-6.97 (m, 1H), 5.95 (d, J = 16.4 Hz, 1H), 5.37 (dd, J = 16.4, 10.0 Hz, 1H), 4.38 (t, J = 7.2 Hz, 2H), 1.94 (d, J = 7.2 Hz, 3H), 1.81-1.76 (m, 2H), 1.53-1.47 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H) ppm. LC-MS (ESI): m/z [M+H]⁺calcd. For: C₁₅H₁₉NO₄⁺: 277.13 found: 278.25.




Para-nitro 2-4 dihydroxybenzaldehyde 12. Glacial acetic acid (8 mL, 139 mmol) and fuming nitric acid (7.2 mL, 169 mmol) were mixed together in a 100 mL round bottomed flask and the mixture was cooled to 0 °C using an ice water bath. After 10 minutes of stirring, 2,4-dihydroxybenzaldehyde (2.0 g, 14.5 mmol, 1.0 equiv) was added portion wise over 15 minutes to the solution. The reaction was brought to room temperature (after 1 hour at room temperature there was a strong gas evolution) and was stirred for additional 24 hours. The pink solid precipitate was filtered on a fritted funnel and washed with a small amount of ice-cold water to obtain, the desired compound 12 as a pink solid in 61% yield (1.6 g). ¹H NMR (CDCl₃, 400 MHz, 23 °C): $\delta = 11.66$ (s, 1H); 11.22 (s, 1H); 9.86 (s, 1H);


8.51 (s, 1H); 6.65 (s, 1H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ = 193.9, 168.0, 161.4, 133.5, 124.7, 115.2, 106.1, ppm.




Nitro acid 2c. Nitro aldehyde 12 (1.6 g, 8.74 mmol, 1.0 equiv), was dissolved in DMSO and cooled to 0 °C using an ice water bath. To this solution NaH₂PO₄ (2.9 g, 21.8 mmol, 2.5 equiv) in 7 mL of distilled water, and NaClO₂ (1.9 g, 21 mmol, 2.4 equiv) in 7 mL of distilled water, were added during a period of 10 minutes. The deep yellow mixture was warmed slowly to room temperature and kept stirred over night. The mixture was diluted slowly with saturated aqueous Na₂CO₃ (15 mL), and washed with EtOAc (5 mL). The aqueous layer was acidified to pH 1 by adding HCl 1M at 0 °C and the resulting solution was stored at 0°C for 12 hours. The precipitate was filtered on a fritted funnel and washed with a small amount of ice-cold water to obtain, the desired compound **4** as a yellow solid in 86% yield (1.5 g). ¹H NMR (CD₃OD, 400 MHz, 23 °C): $\delta = 8.71$ (s, 1H); 6.57 (s, 1H); 9.86 (s, 1H). ¹³C NMR (CD₃OD, 100 MHz, 25 °C): $\delta = 171.9$, 169.2, 161.0, 131.0, (x2) 108.1, 106.1 ppm.




Acetonide protected phenol 13. TFAA (7.5 mL, 52.5 mmol, 7.0 equiv) was added slowly to a solution of acid 2c (1.5 g, 7.5 mmol, 1.0 equiv) dissolved in TFA (9.4 mL, 122.2 mmol, 16.3 equiv). Acetone (4.0 mL, 52.5 mmol, 7.0 equiv) was then added and the reaction heated to reflux for 12 hours. The reaction was then allowed to reach room temperature and the volatile were removed under vacuum. The resulting brown solid was dissolved in EtOAc (30 mL), the organic layer was washed with saturated aqueous NaHCO₃ (2 x 15 mL) and the combined organic phases were dried over Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure afforded the desired compound 13 as a brown solid in 83% yield (1.5 g). The desired compound was used without further purification in the next step. ¹H NMR (CDCl₃, 400 MHz, 23 °C): $\delta = 11.17$ (s, 1H); 8.88 (s, 1H); 6.70 (s, 1H): 1.80 (s, 6H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): $\delta = 161.9$, 160.1, 158.9, 129.9, 129.3, 107.8, 106.7, 106.4, 26.1 (x2) ppm.




Synthesis of the trifluoro methansulphonic ester 14. TEA (665 µl, 4.8 mmol, 3.0 equiv) was added to a solution containing phenol 13 (380 mg, 1.6 mmol, 1.0 equiv) in dry CH₂Cl₂ (8 mL) and the mixture was cooled down to 0 °C using an ice water bath. After stirring for 10 minutes, Tf₂O (296 µl, 1.76 mmol, 1.1 equiv) was added dropwise. After complete consumption of the starting phenol 13, as judged by TLC analysis, the reaction was quenched with saturated aqueous NaHCO₃ (10 mL), extracted with CH₂Cl₂ (3 x 20 mL) and the combined organic phases were dried over Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure followed by flash chromatography (silica gel, 80/20 petroleum ether/EtOAc) afforded the desired compound 14 as a yellow solid in 80% yield (470 mg). ¹H NMR (CDCl₃, 400 MHz, 23 °C): δ = 8.88 (s, 1H); 7.11 (s, 1H); 1.85 (s, 6H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ = 160.0, 157.3, 146.8, 129.3 (x2), 113.5 (x2), 112.9, 109.0, 26.1 (x2) ppm.



Alkyne-branched amine 3. A flame dried 100 mL two necked round bottomed flask was charged with Pd(PPh₃)₂Cl₂ (63 mg, 0.09 mmol, 4%), TEA (933 µl, 6.7 mmol, 3.0 equiv) trifluoro methansulphonic ester 14 (830 mg, 2.23 mmol, 1.0 equiv.) and 20 mL of dry THF. Boc-protected alkyne 4 (415 mg, 2.45 mmol, 1.1 equiv) in THF (5 mL) was added over 10 minutes, then a catalytic amount of CuI was added and the mixture heated to reflux. After complete consumption of the starting material 14, as judged by TLC analysis, the reaction was quenched with saturated aqueous NH₄Cl (15 mL) extracted with Et₂O (3 x 30 mL) and the combined organic phases were dried over Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure followed by flash chromatography (silica gel, 75/25 petroleum ether/EtOAc) afforded the desired compound 3 as a yellow solid in 81% yield (700 mg). ¹H NMR (CDCl₃, 400 MHz, 23 °C): $\delta = 8.72$ (s, 1H); 7.19 (s, 1H); 5.10 (bs, 1H); 3.44 (m, 2H); 2.74 (t, J = 6.4 Hz, 2H); 1.79 (s, 6H); 1.47 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): $\delta = 157.4$, 157.2, 154.7, 143.4, 125.9, 122.1, 111.2, 106.8 (x2), 100.5, 78.5, 37.9, 27.2 (x3), 24.8 (x2), 20.6 ppm. The quaternary carbon of tert-butyl group is not visible.




Synthesis of the (*R*)-Pyridil ester 15. (*R*)- α -Methyl-2-pyridinemethanol 5 (64 mg, 0.56 mmol, 1.1 equiv) was added to a solution of NaH (23 mg, 0.56 mmol, 1.1 equiv) in dry THF (5 mL) at 0 °C and the mixture stirred for 10 minutes. Compound 3 (200 mg, 0.513 mmol, 1.0 equiv) was then added as a solid portion wise to the cold mixture, and a deep green coloration appeared. After complete consumption of the starting material 3, as judged by TLC analysis, the reaction was quenched with saturated aqueous NH₄Cl(10 mL) extracted with Et₂O (3 x 20 mL) and the combined organic layers were dried over Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure followed by flash chromatography (silica gel, 65/35 petroleum ether/EtOAc) afforded the desired compound 15 as a light yellow solid in 65% yield (150 mg). ¹H NMR (CDCl₃, 400 MHz, 23 °C): δ = 8.76 (s, 1H); 8.66 (m, 1H); 7.81 (m, 1H); 7.46 (d, *J* = 8 Hz, 1H); 7.35 (m, 1H); 7.17 (s, 1H); 6.27 (q, *J* = 6.8 Hz, 1H); 3.45 (bd, *J* = 6 Hz, 2H); 2.73 (t, *J* = 6.4 Hz, 2H); 1.83 (d, *J* = 6.8 Hz, 3H); 1.49 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): δ = 166.4, 163.0, 157.5, 147.9, 136.5, 126.8 (x2), 122.5 (x2), 122.3, 119.4, 110.6, 74.1, 37.9, 28.5, 20.6, 19.5 (x2) ppm. The quaternary carbon of tert-butyl group is not visible. Two carbons are hidden under the CDCl₃ signal.




Nitro group reduction and Michael acceptor introduction. An oven dried 100 mL round bottomed flask, was charged with Zn dust (261 mg, 3.99 mmol, 14 equiv), the starting (*R*)-pyridil ester **15** (130 mg, 0.285 mmol, 1.0 equiv) and CH₂Cl₂ (8 mL). This slurry was brought to 0°C using an ice water bath, subsequently glacial acetic acid (2.7 mL, 47.46 mmol, 164 equiv) was added slowly, and the mixture warmed to room temperature. After complete consumption of the starting material **15**, as judged by TLC analysis, the reaction was filtered on a celite pad, neutralized with saturated aqueous NaHCO₃ (50 mL) extracted with CH₂Cl₂ (3 x 30 mL) and the combined organic phases were dried over Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure afforded green fluorescent oil that was used directly in the next step. LC-MS: m/z [M]⁺calcd. for C₂₃H₂₇N₃O₅⁺: 425.20; found: 425.95. The crude material was dissolved in dry CH₂Cl₂ (3 mL), added to a 50 mL two necked round bottomed flask containing a solution in dry CH₂Cl₂ (3 mL) of DCC (97 mg, 0.47 mmol, 2.0 equiv), propiolic acid (29 µl, 0.47 mmol, 2.0 equiv) and DMAP (catalytic amount) at 0 °C. After complete consumption of the starting material, as judged by TLC analysis, the reaction was quenched with saturated aqueous NH₄Cl (10 mL) extracted with CH₂Cl₂ (3 x 20 mL) and the combined organic phases were dried organic phases were dried with Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure phases were dried with Na₂SO₄. Filtration and evaporation of the solvent with CH₂Cl₂ (3 x 20 mL) and the combined organic phases were dried with Na₂SO₄. Filtration and evaporation of the solvents under reduced pressure

followed by flash chromatography (silica gel, 55/45 petroleum ether/EtOAc) afforded the desired compound **16** as a light white solid in 52% yield (70 mg) over two steps. LC-MS: m/z [M]⁺calcd. for $C_{26}H_{27}N_3O_6^+$: 477.19; found: 477.90. ¹H (CDCl₃, 400 MHz, 23 °C): $\delta = 10.66$ (bs, 1H); 8.86 (s, 1H); 8.63 (d, J = 4.4 Hz, 1H); 8.46 (s, 1H); 7.83-7.79 (m, 1H); 7.55 (d, J = 7.2 Hz, 1H); 7.04 (s, 1H); 6.24 (q, J = 6.8 Hz, 1H); 3.59-3.47 (m, 2H); 3.01 (s, 1H); 2.75 (t, J = 6.4 Hz, 2H); 1.79 (d, J = 6.8 Hz, 3H); 1.45 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz, 25 °C): $\delta = 168.5$, 159.4, 157.9, 148.0, 138.4, 129.8, 123.3, 121.9, 121.3, 120.6 (x2), 120.4, 98.2, 74.4 (x2), 49.3, 39.4, 33.9, 30.9, 29.7, 28.4 (x3), 25.6, 24.9, 21.8, 21.1 (x2) ppm.



Cy3-RA1 (8)

Cy3-RA1 (8): Boc-group removal and coupling to the fluorogenic probe. An oven dried 25 mL round bottomed flask containing the Michael acceptor 16 (70 mg, 0.146 mmol, 1.0 equiv) was charged with dry CH₂Cl₂ (3 mL) and brought to 0°C using an ice water bath. To the cold solution was added TFA (3 mL) slowly, over 5 minutes. After complete consumption of the starting material 16, as judged by TLC analysis, the reaction was allowed to reach room temperature and the volatiles were removed under vacuum. The crude material (7) was not isolated but used directly in the next step. LC-MS: $m/z [M]^+$ calcd. for $C_{21}H_{19}N_3O_4^+$: 377.19; found: 377.89. The crude amine 7 (35 mg, 0.092 mmol, 1.0 equiv) was taken up in dry DMF (3 mL) and DIPEA (36 µl, 0.20 mmol, 2.2 equiv) was added. This mixture was transferred via syringe to a solution in dry DFM (3 mL) of HATU (46 mg, 0.120 mmol, 1.2 equiv) and the cyanine-based fluorophore Cy3CO₂H 6 (64 mg, 0.110 mmol, 1.2 equiv), the reaction was then stirred over night. The reaction was followed by LC-MS and after complete consumption of the starting amine, the solvent was removed under vacuum and the residue directly purified by HPLC (20-80% CH₃CN in water gradient in 50 min, flow: 2 mL/min, DiscoveryR HS C18, 5 µm, 5 cm x 10.0 mm). ¹H NMR (Acetone-d6, 400 MHz, 23 °C): $\delta = 8.48$ (d, J = 4 Hz, 1H); 8.45 (t, J = 13.6 Hz, 1H); 8.32 (d, J = 6.4 Hz, 1H); 7.75 (t, J = 7.6 Hz, 1H); 7.48 (m, 3H); 7.34-7.17 (m, 8H); 6.80- 6.77 (m, 1H); 6.72 (d, J = 14 Hz, 1H); 6.07 (q, J = 6.4 Hz, 1H); 4.14-4.03 (m, 2H); 3.67 (m, 4H); 3.42 (m, 3H); 3.07-3.02 (m, 2H); 2.68 (s, 1H); 2.61 (m, 2H); 2.34 (m, 2H); 1.69 (s, 10H); 1.60 (d, J = 6.4 Hz, 3H); 0.73 (s, 6H) ppm. The signals corresponding to OH and NH are not visible. ¹³C NMR (Acetone-d6, 100 MHz, 23 °C): $\delta = 175.9$, 175.2, 173.5, 160.4, 151.7, 149.9, 143.9, 142.9, 141.8, 138.2 (x2), 129.6 (x 2), 126.2 (x 2), 125.8, 124.0 (x2), 123.2 (x2), 121.3 (x2), 121.0, 112.1 (x2), 104.5, 104.0, 76.3, 75.3, 50.1, 50.1, 46.3, 44.6, 38.6, 35.7, 34.2, 32.7, 32.2, 31.7, 27.4 (x6), 25.7, 23.3, 21.8, 20.9 (x2) ppm. LC-MS: m/z $[M]^+$ calcd. for $C_{50}H_{52}N_5O_5^+$: 802.40; found: 802.21; 401.80 $[M/2]^{+2}$



Biotin-RA1 (9)

Biotin-RA1 (9): Boc-group removal and coupling to Biotin. An oven dried 25 mL round bottomed flask containing the Michael acceptor 16 (70 mg, 0.146 mmol, 1.0 equiv) was charged with dry CH₂Cl₂ (3 mL) and brought to 0°C using an ice water bath. To the cold solution was added TFA (3 mL) slowly, over 5 minutes. After complete consumption of the starting material 16, as judged by TLC analysis, the reaction was allowed to reach room temperature and the volatiles were removed under vacuum. The crude material (7) was not isolated but used directly in the next step. LC-MS: m/z $[M]^+$ calcd. for $C_{21}H_{19}N_3O_4^+$: 377.19; found: 377.89. The crude amine 7 (20 mg, 0.053 mmol, 1.0 equiv) was taken up in dry DMF (3 mL) DIPEA (11 µl, 0.063 mmol, 1.2 equiv) and then BiotinOSu (22 mg, 0.063 mmol, 2.0 equiv) was added, the reaction was then stirred over night. The reaction was followed by LC-MS and after complete consumption of the starting amine, the solvent was removed under vacuum and the residue directly purified by HPLC (20-80% CH₃CN in water gradient in 50 min, flow: 2 mL/min, DiscoveryR HS C18, 5µm, 5 cm x 10.0 mm). ¹H NMR (Acetone-d⁶, 400 MHz, 23 °C) $\delta = 8.56$ (d, J = 5.2 Hz, 1H); 8.47 (s, 1H); 7.93 (m, 1H); 7.62 (d, J = 6.8 Hz, 1H); 7.39 (m, 1H); 6.92 (s, 1H); 6.19 (q, *J* = 6.4 Hz, 1H); 4.41 (dd, J = 7.6, 4.8 Hz, 1H); 4.19 (dd, J = 7.6, 4.4 Hz, 1H); 3.43 (m, 2H); 2.94 (m, 1H); 2.85-2.77 (m, 2H); 2.61-2.57 (m, 3H); 1.68 (d, J = 7.2 Hz, 3H); 1.59-1.51 (m, 4H); 1.34-1.30 (m, 4H) ppm. The signals corresponding to OH and NH are not visible. ¹³C NMR (Acetone-d⁶, 100 MHz, 23 °C) δ = 173.9, 169.1, 159.6, 158.6, 148.7, 139.8, 125.3, 124.8 (x 2), 121.9 (x 2), 121.1, 113.0, 99.6, 78.6, 76.4, 74.6, 62.5 (x 2), 60.9 (x 2), 56.3 (x 2), 40.8 (x 2), 38.5, 36.3, 26.4, 21.8, 20.9, 14.3 ppm. LC-MS: m/z [M]⁺calcd. for C₃₁H₃₃N₅O₆S⁺: 603.69; found: 604.08.

Enzymatic inhibition of EGFR. EGFR was expressed in Sf 9 insect cells as human recombinant GST-fusion protein by means of the baculovirus expression system and was then purified by affinity chromatography using either GSH-agarose (Sigma). The purity was checked by SDS-PAGE/silver staining. For measuring the enzymatic activity of the protein kinase a proprietary protein kinase assay (³³PanQinase® Activity Assay) was used. All kinase assays were performed in 96-well FlashPlates from Perkin–Elmer/NEN (Boston, MA, USA) in a 50 µL reaction volume by using a BeckmanCoulter/Sagian robotic system. The reaction cocktail was pipetted in four steps in the following order: 1) 20 µL of assay buffer, 2) 5 µL of ATP solution (in H₂O), 3) 5 µL of test compound (in 10 % DMSO), and 4) 10 µL of substrate/10 µL of enzyme solution (premixed). The assay for all kinases contained HEPES-NaOH (60 mM), MgCl₂ (pH 7.5, 3 mM), MnCl₂ (3 mM), Na-orthovanadate (3 µM), DTT (1.2 mM), PEG₂₀₀₀₀ (50 µg mL⁻¹), [γ -³³P]-ATP (1 µM, ca. 5×10⁵ cpm per well). The final DMSO concentration was 1 % in all assays. The reaction cocktails were incubated at 30 °C for 80 minutes. The reaction was stopped with H₃PO₄ (50 µL, 2 % v/v). Plates were aspirated and washed two times with H₂O (200 µL) and NaCl (200 µL, 0.9 % w/v). Incorporation of ³³P₁ was determined

with a microplate scintillation counter (Microbeta, Wallac).

For each concentration of the test compounds residual activities (in %) were calculated relative to control values without test compounds. With the set of residual activities (in %) obtained for each test compound, IC_{50} values were calculated by using Quattro Workflow V2.0.1.3 (Quattro Research GmbH, Munich, Germany; <u>www.quattro-research.com</u>). The mathematical model used was "sigmoidal response (variable slope)" with parameters "top" fixed at 100 % and "bottom" at 0 %.

Cellular inhibitions of EGFR auto phosphorylation in epidermoid carcinoma A431 following stimulation with EGFR. Human epidermoid carcinoma cell line A431 was used, which expresses endogenously a high level of EGF-R. Stimulation of these cells with human epidermal growth factor (EGF) results in receptor tyrosine autophosphorylation. A431 cells were plated in RPMI supplemented with 10% FCS in multiwell cell culture plates. After serum-starvation overnight, cells were incubated with compounds in serum-free medium. Prediluted test samples (1,0E-02 M) were added 1:100 to the cell culture medium resulting in a final DMSO concentration of 1%. After 90min incubation at 37°C, cells were stimulated with EGF-R EGF 50 ng/ml for 3 min. Tested range concentration of the compounds was between 1.0E-05 - 3.0E-09 M and Lapatinib was used as the reference compound. Quantification of substrate phosphorylation was assessed in 96well plates via sandwich ELISA using a substrate specific capture antibody and an anti-phosphotyrosine detection antibody. Raw data were converted into percent substrate phosphorylation relative to High controls, which were set to 100%. IC₅₀ values were determined using GraphPad Prism 5.01 software with constrain of bottom to 0 and top to 100 using a nonlinear regression curve fit with variable hill slope. The equation is a four-parameter logistic equation. The average of three experiments was used to calculate the IC_{50} .

Protein kinase covalent labeling with Cy3-RA1 (8): Protein kinases human EGFR +strep-tag (Genway GWB-297EF6), ERBB2-HIS tag (Life Technologies, PV3366), JAK3 his tag (Millipore, 14629), CHK2 his tag (Calbiochem, cat: 220487) and Bovine Carbonic Anhydrase (Sigma) were diluted to 300 nM in the following buffer: 50 mM HEPES, pH 7.4, 3 mM MgCl₂, 3 mM MnCl₂, 3 μ M Na- orthovanadate, 5 mM DTT.

The Cy3 labeled inhibitor Cy3-RA1 (8) was added to a final concentration of 200 nM and the labeling reaction was incubated 30 min at 37 °C on a final volume of 25 μ L.

After incubation was completed, denaturing sample buffer was added to the reaction and the samples were heat denatured at 95 °C for 5 minutes. Then the samples were loaded on SDS NuPAGE, 4-12% Acrylamide Bis (Life Technologies) and separated by electrophoresis.

Once the electrophoresis ended, the gel was dismounted, fixed and scanned on Ettan DIGE Imager (GE Healthcare) using appropriate light filters for Cy3. Finally the gel was stained with silver nitrate using Plus one Silver staining kit for Proteins (GE Healthcare).

Cellular imaging of kinases

Experimental Procedures with HEK293T cells

Background labeling in HEK cells with Cy3-RA1 (8) probe. HEK293T cells maintained in 10% FBS in DMEM (Invitrogen) at 37 °C under 5% CO₂ were incubated at 37 °C for 48 h. Then, the cells were washed three times with DMEM and incubated with 100 nM of **Cy3-RA1 (8)** for 30 min in a CO₂ incubator. After the culture medium was replaced, microscopic images were acquired.

Labeling of cell surface protein (BL-EGFR) with FA and Cy3-RA1 (8). HEK293T cells maintained in 10% FBS in DMEM (Invitrogen) at 37 °C under 5% CO₂ were transfected with the pcDNA3.1(+)-BL-EGFR plasmids using Lipofectamine 2000 (Invitrogen).² After 5–6 h, the culture medium was replaced with DMEM (without phenol red), and the cells were incubated at 37 °C for 24 hours. Then, the cells were washed three times with DMEM and incubated with 500 nM FA^{3,4} and 100 nM of Cy3-RA1 (8) for 30 min in a CO₂ incubator. After the culture medium was replaced, microscopic images were acquired.

Experimental Procedures with BT474 cells

Labeling of Erbb2 protein in live cells with Cy3-RA1 (8). BT474 cells maintained in 10% FBS in DMEM (Invitrogen) at 37 °C under 5% CO₂ were incubated at 37 °C for 48 h. Then, the cells were washed three times with DMEM and incubated with 100 nM of **Cy3-RA1 (8)** for 30 min in a CO₂ incubator. After the culture medium was replaced, microscopic images were acquired. For control experiment, lapatinib (1.0 μ M) was introduced in the cell culture and microscopic images were acquired after 16 hours.

Lapatinib: *N*-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]

² S. Mizukami, S. Watanabe, Y. Hori and K. Kikuchi, J. Am. Chem. Soc. 2009, 131, 5016.

³ S. Watanabe, S. Mizukami, Y. Hori and K. Kikuchi, *Bioconjugate Chem.* 2010, 21, 2320.

⁴ S. Mizukami, S. Watanabe, Y. Akimoto and K. Kikuchi, J. Am. Chem. Soc. 2012, 134, 1623.

quinazolin-4-amine

Labeling of Erbb2 protein in fixed cells with Cy3-RA1. BT474 cells maintained in 10% FBS in DMEM (Invitrogen) at 37 °C under 5% CO₂ were incubated at 37 °C for 48 hours. Then the cells were washed with PBS and fixed with 3.7% formaldehyde for 20 min. After washing with DMEM they were treated with 100 nM of Cy3-RA1 (8) and 1 mM of DAPI in DMEM for 30 min in a CO_2 incubator. After the culture medium was replaced, microscopic images were acquired. For control experiment, lapatinib (1.0 mM) was introduced in the cell culture and microscopic images were acquired after 16 hours.

List of kinase with less than 50% residual binding at 1 μ M (For assay conditions, see ref 12 in the main manuscript).

	Entrez Gene	Percent	
KINOMEscan Gene Symbol	Symbol	Control	inhibition
EGFR(L747-E749del, A750P)	EGFR	0.65	99.35
EGFR(G719S)	EGFR	2.6	97.4
MEK4	MAP2K4	3.8	96.2
EGFR(G719C)	EGFR	4.4	95.6
EGFR(L858R)	EGFR	5.2	94.8
EGFR(L747-T751del,Sins)	EGFR	5.5	94.5
EGFR(L861Q)	EGFR	8.2	91.8
EGFR(S752-I759del)	EGFR	8.7	91.3
EGFR(L747-S752del, P753S)	EGFR	10	90
JAK3(JH1domain-catalytic)	JAK3	10	90
ERBB2	ERBB2	11	89
EGFR	EGFR	12	88
LKB1	STK11	12	88
EGFR(E746-A750del)	EGFR	16	84
BLK	BLK	47	53

Affinity based capture from crude cell extract

HEK293-T cells were grown on DMEM complemented with 10% Calf Fetal Serum (Sigma), 1% PenStrep, 1% non-essential amino acids, 1% Glutamine. When the cells reached confluence after 48-72 h culture at 37° C, 5% CO₂, the monolayer from a T75 cell culture (10⁶ cells approx.) flask was carefully washed with cold, sterile PBS and finally 1 ml of cold lysis buffer was added (20 mM Tris-HCl pH 8, 137 mM NaCl, 10 % glycerol, 1% Triton X100, 2 mM EDTA, 1X HALT Protease inhibitors, Pierce). The flask was gently agitated for 5 min in ice and the cell monolayer scrapped from the flask and recovered on a mini centrifuge tube. The recovered cells were subjected to ultra sonication (three cycled of 30 seconds, on ice) and the protein lysate was centrifuged for 30 min at 14000 rpm, to eliminate cell membranes and cell debris. The supernatant was transferred to a fresh tube, and the soluble cytosolic proteins were quantified by Bradford assay.

A sample of crude cell lysate (10µg, 8 µL) was diluted in buffer Kinase (50 mM HEPES pH 7.4, 3 mM MnCl₂, 3 mM MgCl₂, 3 µM Na-orthovanadate, 2 mM DTT) complemented with 1x HALT protease

inhibitor (Pierce) to a final volume of 20 μ L. Recombinant ErbB2 (# PV3366, Life Technologies) was added to the cell extract to a final concentration of 100 nM. RA1-biotin (9) or biotin were added to the crude extract to a final concentration of 1 μ M and the samples were incubated on a rotation wheel for 30 min at room temperature. After incubation, 50 μ l of streptavidin coated magnetic beads MyOne Tm (Invitrogen, Life Technologies) were washed three times with 20 mM Tris-HCI, pH 7.4, NaCl 2 M and the beads were added to the crude cell extracts. The mixture was incubated on the rotation wheel for another 30 min period, to allow streptavidin - biotin capture. Then the beads were washed 5 times with 100 μ l of kinase buffer and 5 times with100 μ l of 20 mM Tris-HCI, pH 7.4, NaCl 2 M. The magnetic beads were re-suspended in 50 μ l of HBS and treated to MS analysis according to the method reported by Fischer et al. Journal of Proteome Resarch. 2010, 9, 806-817. The experiment was also performed without the addition of ErbB2 and with ErbB2 but using biotin instead of biotin-RA1 (9). The MS results were ranked by metascore for the sample with ErbB2 and compared to the other two samples (Tables S1). Results with less than four peptide fragment per hit were removed.

 Table S1.
 Meta score for MS analysis of protein pull-down from HEK cell lystate.

Accession Name Meta Score Meta Score <th></th> <th>ERBB2</th> <th>-</th> <th>+</th> <th>+</th>		ERBB2	-	+	+
P06733JENOA, HUMAN Alpha-enolase OS-Homo sapiens GN-END1 PE-1 SV-2 772 1285 244 P04254(K2C1, HUMAN Keratin, type It cytoskeletal 10.5-Homo sapiens GN-KKT1 PE-1 SV-6 1131 1204 56 P08371(TBB4B, HUMAN Tubulin beta Ada OS-Homo sapiens GN-TUBB PE-1 SV-1 554 1022 423 P08570(VIME, HUMAN Wimentin OS-Homo sapiens GN-TUBB PE-1 SV-2 0 1022 423 P08570(VIME, HUMAN Wimentin OS-Homo sapiens GN-TUBB PE-1 SV-2 0 1022 423 P0850(VIME, HUMAN Wimentin OS-Homo sapiens GN-TUBB PE-1 SV-2 1067 960 287 P35527K1C3 HUMAN Keratin, type 1 cytoskeletal 9 OS-Homo sapiens GN-HKT9 PE-1 SV-4 630 890 512 P3858/TBA18, HUMAN Keratin, type 1 cytoskeletal 9 OS-Homo sapiens GN-HKT9 PE-1 SV-4 620 762 138 P073001HS930A, HUMAN Keratin, type 1 cytoskeletal 9 OS-Homo sapiens GN-HKE72 PE-1 SV-4 620 772 148 P07301HS930A, HUMAN Heat shock protein HSP 90 alpha OS-Homo sapiens GN-HSP30A1 PE-1 SV-5 434 739 233 P07301HS930A, HUMAN Heat shock protein HSP 90 alpha OS-Homo sapiens GN-HSP30A1 PE-1 SV-2	Accession	Name Biotin-TA1	+ Meta Score	+ Meta Score	Meta Score
P06733JENOA, HUMAN Alpha-enolase OS-Homo sapiens GN-END1 PE-1 SV-2 772 1285 244 P04254(K2C1, HUMAN Keratin, type It cytoskeletal 10.5-Homo sapiens GN-KKT1 PE-1 SV-6 1131 1204 56 P08371(TBB4B, HUMAN Tubulin beta Ada OS-Homo sapiens GN-TUBB PE-1 SV-1 554 1022 423 P08570(VIME, HUMAN Wimentin OS-Homo sapiens GN-TUBB PE-1 SV-2 0 1022 423 P08570(VIME, HUMAN Wimentin OS-Homo sapiens GN-TUBB PE-1 SV-2 0 1022 423 P0850(VIME, HUMAN Wimentin OS-Homo sapiens GN-TUBB PE-1 SV-2 1067 960 287 P35527K1C3 HUMAN Keratin, type 1 cytoskeletal 9 OS-Homo sapiens GN-HKT9 PE-1 SV-4 630 890 512 P3858/TBA18, HUMAN Keratin, type 1 cytoskeletal 9 OS-Homo sapiens GN-HKT9 PE-1 SV-4 620 762 138 P073001HS930A, HUMAN Keratin, type 1 cytoskeletal 9 OS-Homo sapiens GN-HKE72 PE-1 SV-4 620 772 148 P07301HS930A, HUMAN Heat shock protein HSP 90 alpha OS-Homo sapiens GN-HSP30A1 PE-1 SV-5 434 739 233 P07301HS930A, HUMAN Heat shock protein HSP 90 alpha OS-Homo sapiens GN-HSP30A1 PE-1 SV-2	P08107 HSP71 HUMAN	Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5	2271	3055	1691
P66371(TB4B4 HUMAN Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=1 554 1029 432 P07437TB85 HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 0 1022 423 P076870/WE HUMAN Vimentin OS=Homo sapiens GN=TUBB PE=1 SV=2 0 1022 423 P08697(ID46) HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=3 781 933 411 P136969(CH60, HUMAN Keratin, type Lytokeletal 90 OS=Homo sapiens GN=KTP1 PE=1 SV=3 781 933 441 P13696[F2, HUMAN Keratin, type Lytokeletal 10 OS=Homo sapiens GN=KTP1 DE=1 SV=4 262 752 138 P07900(HS00, HUMAN Leongation factor 2 OS=Homo sapiens GN=KTP1 DE1 SV=3 606 797 514 P36381(ACT HUMAN Leatinc tytoplasmic 2 OS=Homo sapiens GN=KTP300A1 PE=1 SV=1 607 711 441 E9R43(ESPK42, HUMAN Heat shock protein OS=Homo sapiens GN=KGP40H PE=3 0 644 274 P2231(LDBA1 HUMAN Heat shock protein SP 0-alpha OS=Homo sapiens GN=LDDA PE=1 SV=2 0 644 274 P2231(HDBA1 HUMAN Heat shock protein KP9 0-beta OS=Homo sapiens GN=LDDA PE=1 SV=2 <td>P06733 ENOA HUMAN</td> <td>Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2</td> <td>772</td> <td>1265</td> <td>244</td>	P06733 ENOA HUMAN	Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2	772	1265	244
P07437TB85 HUMAN Tubulin beta chain OS+Homo sapiens GN=TUBB PE=1 SV=2 0 1022 423 P08670IVIME_HUMAN Vimentin OS+Homo sapiens GN=VIM PE=1 SV=4 631 959 91 P108090L460_HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=KRT9 DE=1 SV=3 1067 860 287 P35527[K103_HUMAN Keratin, type 1 cytoskeletal 9 OS=Homo sapiens GN=KRT9 DE=1 SV=3 761 933 411 P3563[K101_HUMAN Keratin, type 1 cytoskeletal 9 OS=Homo sapiens GN=KRT9 DE=1 SV=4 606 797 514 P13638[K101_HUMAN Hubuin alpha-1B chain OS=Homo sapiens GN=KERT9 DE=1 SV=1 606 797 514 P0380[HS20_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP30A1 PE=1 SV=5 434 733 293 P07800[HS30A_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSP30A1 PE=1 SV=1 607 711 441 E9PKE3[E9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=UBA1 PE=1 SV=3 0 644 274 P22314[LOC1_HUMAN Attic, xcplosamic 2 OS=Homo sapiens GN=HSPA0 PE=1 SV=3 0 644 274 P04075[ALD0A_HUMAN File modifiler-activating enzyme	P04264 K2C1_HUMAN	Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6	1131	1204	56
P08670/UME_HUMAN Vimentin OS=Homo saplens GN=VM PE=1 SV=4 631 655 91 P10809(CH60_HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo saplens GN=KR19 PE=1 SV=2 1067 950 287 P35527[K1C2_HUMAN Keratin, type I cytoskeletal 10 OS=Homo saplens GN=KR19 PE=1 SV=3 761 633 411 P13645[K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo saplens GN=KR19 PE=1 SV=6 430 880 512 P68533[TBA1B_HUMAN Elongation factor 2 OS=Homo saplens GN=KR19 PE=1 SV=4 262 752 138 P07800[H590A_HUMAN Heat shock protein HSP 90-alpha OS=Homo saplens GN=KSP90A1 PE=1 SV=5 434 733 293 P63261[ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo saplens GN=KDF90A2 PE=3 SV=1 0 765 269 G10caradiderlyde-3-phosphate derivgrogenase OS=Homo saplens GN=KDAP DE=3 SV=1 0 644 274 P2214[UBA1 HUMAN Heat shock cognate 71 kDa protein OS=Homo saplens GN=LBAP DE=1 SV=3 105 624 243 P04075[ALDOA_HUMAN Fructose-bisphosphate derivgrogenase GN=LDOA PE=1 SV=2 366 557 118 P0238[H590B_HUMAN Heat shock protein HSP 90-beta OS=Homo saplens GN=LBAP	P68371 TBB4B_HUMAN	Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=1	554	1029	432
P10800[CH60_HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 1067 950 287 P35527[K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 781 933 411 P13645[K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT9 PE=1 SV=3 781 933 411 P13645[K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT9 PE=1 SV=4 460 797 514 P683361[BA1B_HUMAN Tubulin alpha-18 chain OS=Homo sapiens GN=KRT9 PE=1 SV=4 262 752 138 P07900[HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=KFT9 PE=1 SV=4 262 752 138 P07900[HS90A_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=KFR9 PE=3 SV=1 0 765 269 P22314[UBA1_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=KCPDH PE=3 0 644 274 P22314[UBA1_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=LADDA PE=1 SV=3 152 624 243 P04075[k1DAG_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=LDHA PE=1 SV=2 366 567 118 P04075[k1DAG_HUMAN	P07437 TBB5 HUMAN	Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2	0	1022	423
P35527/K1C2_HUMAN Keratin, type I cytoskeletal 9 OS+Homo sapiens GN=RT19 PE=1 SV=3 781 933 411 P13645/K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 430 890 512 P68633[TBA1B_HUMAN Tubulin alpha-1B_chain OS=Homo sapiens GN=KRT10 PE=1 SV=1 606 797 514 P1363[EF2_HUMAN Elongation factor 2 OS=Homo sapiens GN=EE72 PE=1 SV=4 262 752 138 P07900[H590A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP30A1 PE=1 SV=1 607 711 441 E9PKE3[E9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSP30 ES-3 SV=1 0 644 274 P22314/UBA1_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=LBA1 PE=1 SV=3 152 624 243 P04736/LDOA_HUMAN Fuctose-bisphosphate dehydrogenase OS=Homo sapiens GN=LBA1 PE=1 SV=2 0 644 274 P02314/UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=LBA1 PE=1 SV=2 3 624 243 P04736/LDOA_HUMAN Heat shock protein Kinase edb-S OS=Homo sapiens GN=LBA1 PE=1 SV=2 0 644 274 528 266 57	P08670 VIME_HUMAN	Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4	631	959	91
P13645[K1C10_HUMAN Keratin, type 1 cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 430 860 512 P68363[TBA1B_HUMAN Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 606 797 514 P13639[EF2_HUMAN Elongation factor 2 OS=Homo sapiens GN=EF2 PE=1 SV=4 262 752 138 P07200[HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP30A1 PE=1 SV=5 434 739 2293 P63261[ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo sapiens GN=HSP30A1 PE=1 SV=1 607 711 4441 E9PKE3[E9PKE3_HUMAN Heat shock content on SSHomo sapiens GN=HSPAP PE=3 SV=1 0 705 269 274U14[E7EUT4_HUMAN Heat shock content on SSHomo sapiens GN=ALDA PE=1 SV=3 162 624 243 P04075[ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=HSP90AB1 PE=1 SV=2 366 567 118 P0838[HS908_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=LBAP PE=1 SV=2 366 507 118 P04075[ALDOA_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=2 365 0 116 P04075[ALDOA_HUMAN Receptor tyrosine-p	P10809 CH60_HUMAN	60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2	1067	950	287
P68363[TBA1B HUMAN Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 606 797 514 P13639[EF2_HUMAN Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 262 752 138 P07300[HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 434 739 293 P03261[ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 607 711 441 E9PKE3[E9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=ACTG1 PE=1 SV=1 607 705 269 CityceraldErtyde-3_phosphate dehydrogenase CS=Homo sapiens GN=GAPDH PE=3 0 644 274 P22314[UBA1_HUMAN Ubiquitri-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 152 624 243 P04075[ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=HSP90AB1 PE=1 SV=2 366 557 118 P04075[ALDOA_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=2 0 505 0 P14618-2(KPYM_HUMAN Receptor tyrosine-protein kinase etbB-2 OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 505 0 P14618-2(KPYM_HUMAN L-actate d	P35527 K1C9_HUMAN	Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3	781	933	411
P13639[EF2_HUMAN Elongation factor 2 OS+Homo sapiens GN=EEF2 PE=1 SV=4 262 752 138 P07900[HS90A HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 434 739 293 P63261[ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 607 711 441 E9PKE3[E9PKE3_HUMAN Heat shock cognate 71 Kba protein OS=Homo sapiens GN=HSPA8 PE=3 SV=1 0 705 269 27EUT4[E7EUT4_HUMAN Verait Kba protein OS=Homo sapiens GN=HSPA8 PE=3 SV=1 0 644 274 P22314[UBA1_HUMAN Ubiquitin-like modifie-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 152 624 243 P04075[ALDOA_HUMAN Fructose-bisphosphate alcolase A OS=Homo sapiens GN=HSP00AB1 PE=1 SV=2 366 557 118 P0338[LDHA_HUMAN Heat shock protein HSP 90-bate OS=Homo sapiens GN=ERBB2 PE=2 SV=1 0 505 0 P14618-2(KPYM_HUMAN Isoform M1 of Pyruvate kinase iloszymes M1/M2 OS=Homo sapiens GN=ERBB2 PE=2 SV=1 0 505 0 P0338[LDHA_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=EHGDH PE=1 SV=2 165 211 0 344 162	P13645 K1C10_HUMAN	Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6	430	890	512
P07900[HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 4.34 7.39 2.93 P63261[ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 607 711 441 E9PKE3[E9PKE3]_HUMAN Heat shock cognate 71 Iba protein OS=Homo sapiens GN=HSPA8 PE=3 SV=1 0 705 269 Cityperaldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=3 0 644 274 P22314[UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=2 366 557 118 P04075]ALDO_A_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ERB2 PE=2 SV=1 0 565 0 P04338[HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=ERB2 PE=2 SV=1 0 565 0 P04338[HS90B_HUMAN Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=ERB2 PE=2 SV=1 0 565 0 P14618-2[KPFM_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 0 454 226 P07195[LDHB_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=DHB PE=1 SV=2 0 454 226 P01338[LDHA_HUMAN L-lactate d	P68363 TBA1B_HUMAN	Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1	606	797	514
P63261JACTG HUMAN Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1 607 711 441 E9PKE3JE9PKE3 HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=KSPA8 PE=3 SV=1 0 705 269 E7EUT4[E7EUT4_HUMAN Vertal dehydrogenase OS=Homo sapiens GN=GAPDH PE=3 0 644 274 P22314[UBA1 HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=2 366 557 118 P04075[ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=LDOA PE=1 SV=2 366 557 118 P04075[ALDOA_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=KRB2 PE=2 SV=1 0 506 0 P14618-2[KPVM_HUMAN Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERB2 PE=2 SV=1 0 506 0 P14618-2[KPVM_HUMAN Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM 0 476 115 P0038JLDHA_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=LDHA PE=1 SV=2 0 454 226 P01195[LDHB_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=LPHGDH PE=1 SV=4 383 379 209 Isoform Short of Heterogeneous nuclear rifon	P13639 EF2_HUMAN	Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4	262	752	138
E9PKE3JE9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=3 SV=1 0 705 269 E7EUT4[E7EUT4_HUMAN SV=1 0 644 274 P22314[UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 152 624 243 P04075[ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=LBAD PE=1 SV=2 366 557 118 P08238[HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 322 528 246 B4DTR1[B4DTR1_HUMAN Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERB2 PE=2 SV=1 0 505 0 P14618-2]KPYM_HUMAN Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=ERB2 PE=2 SV=1 0 454 226 P07195]LDHB_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 0 454 226 P07195]LDHB_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=ENBE PV=2 185 450 211 O43175]SERA_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=ENBE PV=2 186 450 211 O43175]SERA_HUMAN Endoplasmin OS=Homo sapiens GN=ENBE PUS=1 0 344 162	P07900 HS90A_HUMAN	Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5	434	739	293
Cityceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=3 0 644 274 P22314[UBA1_HUMAN SV=1 0 644 274 P22314[UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 152 624 243 P04075[JALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=LDOA PE=1 SV=2 366 557 118 P08238[HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 322 528 246 B4DTR1[B4DTR1_HUMAN Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 505 0 P14618-2[KPYM_HUMAN Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 454 226 P07195[LDHB_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 0 454 226 P07195[LDHB_HUMAN L-lactate dehydrogenase B chain OS=Homo sapiens GN=PHGDH PE=1 SV=2 383 379 209 00839-2[HNRPU_HUMAN L-lactate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=2 384 162 014225[SENPL_HUMAN Endoplasmin OS=Homo sapiens GN=ERB2 PE=1 SV=1 0 <td>P63261 ACTG_HUMAN</td> <td>Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1</td> <td>607</td> <td>711</td> <td>441</td>	P63261 ACTG_HUMAN	Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1 PE=1 SV=1	607	711	441
E7EUT4[E7EUT4_HUMAN SV=1 0 644 274 P22314[UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 152 624 243 P04075[ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 366 557 118 P08238[HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 322 528 246 B4DTR1[B4DTR1_HUMAN Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 605 0 P14618-2]KPYM_HUMAN Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PEMBM 0 476 1115 P00338[LDHA_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=PLDHA PE=1 SV=2 0 454 226 P07195[LDHB_HUMAN L-lactate dehydrogenase B chain OS=Homo sapiens GN=PHGDH PE=1 SV=2 185 450 211 O43175]SERA_HUMAN D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 383 379 208 19850/MSTNot of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens 1199 344 162 P14625[ENPL_HUMAN Endoplasmin OS=Homo sapiens GN=CKB PE=1	E9PKE3 E9PKE3_HUMAN	Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=3 SV=1	0	705	269
P22314/UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3 152 624 243 P04075/ALDOA_HUMAN Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 366 557 118 P08238/HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 322 528 246 B4DTR1/B4DTR1_HUMAN Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 505 0 P14618-2/KPYM_HUMAN Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 456 226 P07195/ILDHB_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=ERB82 PE=2 SV=1 0 456 226 P07195/ILDHB_HUMAN L-lactate dehydrogenase A chain OS=Homo sapiens GN=ENDH PE=1 SV=2 185 450 211 O43175/ISERA_HUMAN D-3-phosphogiycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 383 379 209 Isoform Snot of Heterogeneous nuclear nbonucleoprotein U OS=Homo sapiens 139 344 162 P14625/ENPL_HUMAN Endoplasmin OS=Homo sapiens GN=ERB PE1 SV=1 0 340 0 P12277/KCRB_HUMAN	E7EUT4IE7EUT4 HUMAN		0	644	274
P04075/ALDOA_HUMANFructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2366557118P06238/HS90B_HUMANHeat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4322528246B4DTR1 B4DTR1_HUMANReceptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERB82 PE=2 SV=105050P14618-2 KPYM_HUMANIsoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM0476115P00338 LDHA_HUMANL-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=20454226P07195 LDHB_HUMANL-lactate dehydrogenase A chain OS=Homo sapiens GN=PLGDH PE=1 SV=21854502111043175 SERA_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PLGDH PE=1 SV=438337920900839-2 HNRPU_HUMANGN=HNRNPUGN=HNRNPU10 OS=Homo sapiens GN=PLGDH PE=1 SV=438337920900839-2 HNRPU_HUMANEndoplasmin OS=Homo sapiens GN=KB PE=1 SV=1034000P12277 KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=PPLA PE=1 SV=2352332197A8K092]ABK092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940PPDS1[E9PBS1_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=CPC PE=1 SV=4146290337P08865 RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=CPC PE=1 SV=4028674B4DEM7[B4DEM7_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=CPC PE=1 SV=4028674 <td< td=""><td>P22314 UBA1 HUMAN</td><td>Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3</td><td>152</td><td>624</td><td>243</td></td<>	P22314 UBA1 HUMAN	Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV=3	152	624	243
B4DTR1_HUMANReceptor tyrosine-protein kinase erbB-2 OS-Homo sapiens GN=ERBB2 PE=2 SV=105050P14618-2 KPYM_HUMANIsoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM0476115P00338 LDHA_HUMANL-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=20454226P07195 LDHB_HUMANL-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2185450211O43175 SERA_HUMANL-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2185450211O43175 SERA_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4383379209000839-2 HNRPU_HUMANEndoplasmin Short of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens139344162P14625 ENPL_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277 KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940P085072 TERA_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1152293126P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=CT8 PE=1 SV=4028674B4DEM7 B4DEM7_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=CT8 PE=2 SV=1027971P52922 IMA2_HUMANHUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=CCP PE=1 SV=4028674			366	557	118
P14618-2 KPYM_HUMANIsoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM0476115P00338 LDHA_HUMANL-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=20454226P07195 LDHB_HUMANL-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2185450211O43175 SERA_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=438337920900839-2 HNRPU_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=438337920900839-2 HNRPU_HUMANEndoplasmin OS=Homo sapiens GN=ENFIGDH PE=1 SV=438337920900839-2 HNRPU_HUMANEndoplasmin OS=Homo sapiens GN=KB PE=1 SV=103400P12277 KCRB_HUMANEndoplasmin OS=Homo sapiens GN=CKB PE=1 SV=103400P12277 KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092 A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940Pbosphoribosylaminoimidazole-succincarboxamide synthase (Fragment) OS=Homo152293126P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=CCP PE=1 SV=414629037P08865 RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=RCP PE=1 SV=4028674B4DEM7 B4DEM7_HUMANT-complex protein A OS=Homo sapiens GN=CCT8 PE=2 SV=1 </td <td></td> <td></td> <td>322</td> <td></td> <td></td>			322		
P00338 LDHA_HUMANL-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=20454226P07195 LDHB_HUMANL-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2185450211O43175 SERA_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4383379209Q00839-2 HNRPU_HUMAND-3-phosphoglycerate dehydrogeneous nucleor ribonucleoprotein U OS=Homo sapiens139344162Q00839-2 HNRPU_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277 KCRB_HUMANEndoplasmin OS=Homo sapiens GN=CKB PE=1 SV=103400P12277 KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092 A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940PPDS51 E9PBS1_HUMANsapiens GN=PAICS PE=4 SV=1152293126P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4028674P08865 RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=CT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=311624291	B4DTR1 B4DTR1 HUMAN	Receptor tyrosine-protein kinase erbB-2 OS=Homo sapiens GN=ERBB2 PE=2 SV=1	0	505	0
P07195[LDHB_HUMANL-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2185450211O43175]SERA_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4383379209Q00839-2]HNRPU_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4383379209Q00839-2]HNRPU_HUMANSoft Abort of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens139344162P14625]ENPL_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277]KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092]A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1152293126P55072]TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=414629037P08865]RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4028674B4DEM7]B4DEM7_HUMANImportin subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=RAN PE=1 SV=311624291P62826]RAN_HUMANGTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=311624291	P14618-2 KPYM_HUMAN	Isoform M1 of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM	0	476	115
O43175JSERA_HUMAND-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4383379209Q00839-2JHNRPU_HUMANIsoform Short of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens139344162P14625JENPL_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277JKCRB_HUMANEndoplasmin OS=Homo sapiens GN=CKB PE=1 SV=103400P12277JKCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937JPPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092JA8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940PDssphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1152293126P55072JTERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4028674B4DEM7JB4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292JIMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=RAN PE=1 SV=311624291P62826JRAN_HUMANGTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=311624291	P00338 LDHA_HUMAN	L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2	0	454	226
Q00839-2 HNRPU_HUMANIsoform Short of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU139344162P14625 ENPL_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277 KCRB_HUMANEndoplasmin OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092 A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940PPBS1 E9PBS1_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1152293126P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4028674B4DEM7 B4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=311624291	P07195 LDHB_HUMAN	L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2	185	450	211
Q00839-2 HNRPU_HUMANGN=HNRNPU139344162P14625 ENPL_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277 KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092 A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1152293126P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4028674B4DEM7 B4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=311624291P62826[RAN_HUMANGTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=311624291	O43175 SERA_HUMAN	D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4	383	379	209
P14625[ENPL_HUMANEndoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=103400P12277]KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937]PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092]A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1152293126P55072]TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=CCP PE=1 SV=4028674B4DEM7]B4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292]IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=311624291	Q00839-2IHNRPU HUMAN		139	344	162
P12277/KCRB_HUMANCreatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=130633591P62937/PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092/A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1152293126P55072/TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=414629037P08865/RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4028674B4DEM7/B4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292/IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=311624291	· –				
P62937 PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2352332197A8K092 A8K092_HUMANATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1472940Posphoribosylaminomidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1152293126P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=414629037P08865 RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4028674B4DEM7 B4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=311624291P62826 RAN_HUMANGTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=311624291	·		306		
A8K092 A8K092 HUMAN ATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1 47 294 0 Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo sapiens GN=PAICS PE=4 SV=1 152 293 126 P55072 TERA_HUMAN Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4 146 290 37 P08865 RSSA_HUMAN 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 0 286 74 B4DEM7 B4DEM7_HUMAN T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1 0 279 71 P52292 IMA2_HUMAN Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=4 182 255 96 P62826[RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 116 242 91			352	332	197
Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo 152 293 126 E9PBS1[E9PBS1_HUMAN sapiens GN=PAICS PE=4 SV=1 152 293 126 P55072[TERA_HUMAN Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=4 146 290 37 P08865[RSSA_HUMAN 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 0 286 74 B4DEM7[B4DEM7_HUMAN T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1 0 279 71 P52292[IMA2_HUMAN Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 182 255 96 P62826[RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 116 242 91	· -	ATP synthase subunit alpha OS=Homo sapiens GN=ATP5A1 PE=2 SV=1	47	294	0
P55072 TERA_HUMANTransitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV=414629037P08865 RSSA_HUMAN40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4028674B4DEM7 B4DEM7_HUMANT-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1027971P52292 IMA2_HUMANImportin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=118225596P62826 RAN_HUMANGTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=311624291		Phosphoribosylaminoimidazole-succinocarboxamide synthase (Fragment) OS=Homo	152	203	126
P08865JRSSA_HUMAN 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 0 286 74 B4DEM7JB4DEM7_HUMAN T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1 0 279 71 P52292JIMA2_HUMAN Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 182 255 96 P62826JRAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 116 242 91	• •				
B4DEM7[B4DEM7_HUMAN T-complex protein 1 subunit theta OS=Homo sapiens GN=CCT8 PE=2 SV=1 0 279 71 P52292 IMA2_HUMAN Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 182 255 96 P62826]RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 116 242 91					
P52292 IMA2_HUMAN Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 182 255 96 P62826 RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 116 242 91			-		
P62826 RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 116 242 91	·		-		
	P40227 TCPZ HUMAN	T-complex protein 1 subunit zeta OS=Homo sapiens GN=KAN PE=1 SV=3	0	242	60

Electronic Supplementary Material (ESI) for Chemical Science This journal is © The Royal Society of Chemistry 2013